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ABSTRACT
The discovery of genes linked with a large array of diseases has been accelerated by genome-wide
association studies (GWAS), in which genetic variants in different individuals are examined for relationship
with a specified phenotype. Most GWAS analyses require modeling the association between single nucleotide
polymorphisms (SNPs) and the outcome of interest as additive, dominant, or recessive. In general, this
relationship is not known. The genotypes of a marker can be regarded as ordered categorical. An additive
model assumes linearity, and approaches that categorize the data ignore order information, resulting in loss
of power. Therefore, a method that only assumes a monotonic relationship between SNPs and the outcome
of interest may be more robust and powerful than standard approaches. In this thesis, we explore the use
of such a method using pharmacogenomics data from a clinical trial that randomized 1858 HIV-infected
patients to one of four antiretroviral regimen combinations (tenofovir+efavirenz, tenofovir+atazanavir,
abacavir+efaverinz, and abacavir+atazanavir). We are specifically interested in detecting SNPs that are
associated with tenofovir clearance and creatinine clearance. We assess the performance of the new method
versus the additive, dominant, and recessive models via simulation studies and real data analyses, and
compare and contrast findings.
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CHAPTER I
Introduction and Background
In practice, researchers collect and analyze data of different types, including continuous and categorical
data. To date, various statistical methods have been developed for analysis of ordinal categorical data. Most
of the methods are suited for the analysis of ordered categorical outcomes. Examples of models that are
commonly used to assess the relationship between an ordinal outcome and continuous or categorical predictors
include the cumulative logit model, the continuation-ratio model and the proportional odds model [3]. The
treatment of ordinal independent variables is an area that beckons further exploration. Standard regression
models treat ordinal predictors as either continuous or as categorical variables. If ordinal predictors are
treated as categorical variables, order information is ignored, presumably resulting in loss of power. If
treated as continuous variables, a linear relationship between the outcome and predictor is assumed which
may not be desirable.
Alternative methods have been proposed to handle ordinal predictors. Walter et al [14] describe a
coding scheme that can be used to define contrasts in the dependent variable between successive levels of
the predictor, or to identify critical threshold values of the predictors at which significant changes occur
in the response. Other methods specific to cases where both the outcome and the predictor are ordinal
include the use of splines to impose monotonicity in transformed variables [11], isotonic regression [4], use
of latent variables, joint modeling of the ordinal predictor (X) and the outcome (Y) conditional on other
covariates (Z) [6, 2, 10], Kendalls partial tau [8], an extension of Kendalls partial tau to multivariable Z [7]
and stratifying data according to Z and then computing weighted averages of stratum-specific measures of
association between X and Y [13, 5, 1]. As discussed by Li and Shepherd [9], these methods have limitations.
For instance, the use of splines requires the specification of number and location of knots, the use of latent
variables require the specification of a distribution for the latent variable, and the implementation of some
of these methods require grouping of continuous or multivariable Z into strata, which may lead to loss
of information due to the arbitrary generation of cut-offs on Z. These limitations hence motivated the
development of conditional ordinal by ordinal tests (COBOT) outlined in the subsection that follows.
Conditional Ordinal by Ordinal Test (COBOT)
Li and Shepherd [9] introduced a method for testing the association between two ordinal variables, X
and Y, while adjusting for categorical or continuous covariates, Z. They developed test statistics that can
be used to test for association between X and Y by fitting separate multinomial models of X and Y given
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Z. The motivation is that these two conditional distributions will be independent if there is no relationship
between X and Y conditional on Z. Their first test statistic is based on the comparison of the observed joint
distribution between X and Y with their expected distribution under the null of conditional independence,
while accounting for order information in Y and X. Similarly, the second test statistic is based on fitting
separate models for P (Y |Z) and P (X|Z). Then, the correlation between the residuals from these two models
(i.e., cor(Yi,res, Xi,res)) is calculated. The third test statistic is a variation of the second approach in which
the observed value of each individual (Yi, Xi) is compared with the distribution of possible values of (Y,X)
given covariate zi. Suppose a random value, (Y
′
i , X
′
i), from subject i
′s product distribution is drawn and
then compared with the observed value; in the absence of ties, the pair of data points (Yi, Xi) and (Y
′
i , X
′
i)
is concordant if Xi > X
′
i and Yi > Y
′
i , or if Xi < X
′
i and Yi < Y
′
i , and discordant otherwise. The probabil-
ities of concordance (Ci) and discordance (Di) can be derived under the null of (Yi, Xi) and (Y
′
i , X
′
i) both
following the same product distribution, yielding the third test statistic as the average difference of Ci and
Di across all subjects. Further details on the development and performance of the three test statistics can
be obtained in their paper.
For this study, we present an extension of COBOT, in which the outcome is continuous and the predictor
is ordinal, while adjusting for other covariates. Specifically, we develop an extension of the residual-based
test statistic from COBOT to test for the association between a continuous outcome and an ordinal pre-
dictor. Henceforth, we refer to this method as the residual-based conditional continuous by ordinal test
(CoCoBOT). In the subsequent sections, we introduce the set-up and basic theory of this method and evalu-
ate its performance particularly in a situation where the ordinal predictor is genotype with three categories.
Motivation for Genome Wide Association Studies
Most genome wide association studies (GWAS) of the association between SNPs and a phenotype such
as kidney disease or anti-retroviral (ARV) pharmacokinetics involve the specification of additive, dominant
or recessive model during analysis. In some cases, the genotype can be treated as a categorical or factor
variable. Consider a bi-allelic marker with alleles A and a. The possible genotypes for this marker are A/A,
A/a and a/a. Assuming the effect of an outcome associated with a given genotype is represented by β, an
additive model with the genotypes coded as A/A = 0, A/a = 1, and a/a = 2 indicates that the risk of
the outcome is increased by β (2β) for genotype A/a (a/a). A recessive model with the genotypes coded
as A/A = 0, A/a = 0, and a/a = 1 indicates that two copies of the a allele are required for a β increase
in risk of the outcome. Finally, a dominant model with the genotypes coded as A/A = 0, A/a = 1, and
a/a = 1 indicates that at least one copy of the a allele is required for a β increase in risk of the outcome.
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A categorical model on the other hand models the genotypes using indicator variables. Table 1 below shows
an illustration of these four model specifications:
Table 1: Model specifications for genetic associations
Analysis Model Genotype
A/A A/a a/a
Additive 0 β 2β
Recessive 0 0 β
Dominant 0 β β
Categorical 0 β1 β2
The genotypes of a given marker can be characteristically ordered (0, 1, 2 as in the stated example). The
additive model assumes linearity, while the categorical model ignores the order information of the genotypes.
In light of this, we seek to apply the residual-based CoCoBOT method to analysis of GWAS data, and
compare its performance with the additive, dominant, recessive and categorical models using simulations.
In addition, we use all five models to detect SNPs associated with two phenotypes (tenofovir clearance and
creatinine clearance) using real data and compare results.
In Chapter II, we present a GWAS of tenofovir clearance and creatinine clearance (CrCl) using the
additive model. In Chapter III, we introduce the basic theory of CoCoBOT and a simulation study for
genotype data and compare the power of the CoCoBOT, additive, dominant, recessive and categorical
models to detect genetic associations. In Chapter IV, we present a GWAS case study of tenofovir clearance
and CrCl using the dominant, recessive, categorical and CoCoBOT models in addition to the additive model
and compare results. Finally in Chapter V, we summarize the results from the simulation study and case
study, and the implications of our findings for future research.
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CHAPTER II
Genome-wide Association Study of Tenofovir Pharmacokinetics
and Creatinine Clearance in AIDS Clinical Trials Group Protocol
A5202
In this section, we present a GWAS study conducted concurrently with this work. The study was
motivated by findings from previous studies of HIV-infected patients who are randomized to tenofovir, one of
the commonly used antiretroviral (ARV) drugs. In this chapter, we present a review of the study, methods,
results and conclusions. For our case study (Chapter IV), we perform the same analyses outlined in the
study, except we employ additional models (dominant, recessive, categorical) and also use the residual-based
CoCoBOT method. We ultimately compare the results we obtain using all five models.
Introduction
Tenofovir disoproxil fumarate (TDF) is included among recommended first-line regimens for human im-
munodeficiency virus type 1 (HIV-1) infection [15]. It is converted in vivo to tenofovir, which undergoes
intracellular diphosphorylation to its active moiety, tenofovir diphosphate [16]. Although generally safe,
effective and well tolerated [17-27], some HIV-infected patients prescribed TDF experience declines in cre-
atinine clearance (CrCl) [24, 25, 28-30], particularly in regimens that include an HIV-1 protease inhibitor
plus low-dose ritonavir [24, 25, 29]. In AIDS Clinical Trials Group (ACTG) protocol A5202, median change
in CrCl from baseline to week 96 decreased by 3 mL/min in subjects who received TDF/emtricitabine with
atazanavir/ritonavir, but increased by 5 mL/min in subjects who received TDF/emtricitabine with efavirenz
[25]. Discontinuation or dose reduction of TDF/emtricitabine for changes in renal function in A5202 was
infrequent [25].
Renal elimination of tenofovir involves glomerular filtration and tubular secretion [31]. Tenofovir entry
into proximal tubule cells appears to be mediated by two transporters, solute carrier family 22 member 6
(SLC22A6, previously called organic anion transporter 1 (OAT1 )) and SLC22A7 (previously called OAT2 )
[32]. Renal tubular secretion is mediated by eﬄux transporters including ATP-binding cassette, sub-family
C, member 4 (ABCC4, previously called multidrug resistance protein 4 (MRP4 )) [32], and possibly ABCC2
(previously called multidrug resistance protein 2 (MRP2 )), although the importance of ABCC2 is uncertain
[32]. Declines in CrCl associated with concomitant HIV-1 protease inhibitors may reflect ABCC4 inhibition,
with resultant tenofovir accumulation in proximal tubule cells.
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Several candidate gene studies involving HIV-positive patients have suggested associations between sin-
gle nucleotide polymorphisms (SNPs) and adverse renal effects with tenofovir-containing regimens, although
none would have been significant at P < 0.05 if corrected for multiple comparisons. A study of 30 patients
in France (13 cases and 17 controls) suggested increased risk for proximal renal proximal tubulopathy with
an ABCC2 polymorphism (1249G → A, rs2273697, P = 0.02) [33]. A study of 190 Japanese patients (19
cases and 181 controls) suggested increased risk for renal tubular dysfunction with two polymorphisms in
ABCC2 (-24T → C, rs717620, and 1249 G → A, each P = 0.02) [34]. Analyses of a cohort from Spain,
19 kidney tubular dysfunction cases and 96 controls, suggested increased risk with ABCC2 -24T → C (P
= 0.03) [43], and two polymorphisms in ABCC10 (rs9349256, P = 0.02; and rs2125739, P = 0.05) [35]. In
addition, a study of 30 patients suggested an association between higher peripheral blood mononuclear cell
tenofovir diphosphate concentrations and an ABCC4 polymorphism (3463A → G, rs1751034, P = 0.04)
[22]. Kidney tubular dysfunction included serum creatinine and/or creatinine clearance differences in some
previous reports [33][34] but not in others [29][21]. Previous reports showed limited replication other than
perhaps ABCC2 polymorphisms [33][34].
Here we present two genome-wide association studies (GWAS) based on a cohort of HIV-infected sub-
jects who participated in a prospective randomized clinical trial. The first GWAS considers plasma tenofovir
clearance, and the second considers change in estimated CrCl. Within each GWAS we performed pre-
planned analyses of candidate genes and SNPs. To our knowledge, this is the first GWAS of tenofovir
pharmacokinetics, and the first GWAS of tenofovir-related change in renal function. We identified SNPs
of potential interest, although none were genome-wide significant after Bonferroni correction. Importantly,
polymorphisms previously implicated in tenofovir-associated renal toxicity did not replicate in the present
study.
Methods
Study Subjects
AIDS Clinical Trials Group (ACTG) Protocol A5202 (ClinTrials.gov NCT00118898) was a phase IIIb
equivalence study of four once-daily regimens for initial treatment of HIV-1 infection. Primary results of
A5202 have been previously reported [22, 25]. Briefly, 1,858 HIV-infected subjects were randomized to
receive either TDF/emtricitabine (300 mg/200 mg) or abacavir/lamivudine (600 mg/300 mg), with either
open-label atazanavir (300 mg) plus ritonavir (100 mg), or efavirenz (600 mg). Protocol-defined evaluations
of serum creatinine determinations were performed before entry, at entry, at weeks 4, 8, 16 and 24, and every
12 weeks thereafter until week 96 after the last subject enrolled. Creatinine clearance was calculated using
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the Cockcroft-Gault formula based on ideal body weight [37].
Tenofovir assays and plasma sampling
Pharmacokinetic samples for this analysis include those collected between weeks 4 and 24 of A5202.
A sparse sampling strategy was designed to collect and measure antiretroviral concentrations in 3 plasma
samples per subject. Plasma collection times included a 24-hour post-dose sample followed by an observed-
dose sample 3-4 hours post-dose, and another sample 5-15 hours post-dose. The TDF dose of 300 mg is
equivalent to 245 mg of tenofovir disoproxil and to 136 mg of tenofovir. Steady-state plasma concentrations of
tenofovir were measured using tandem mass spectrometry detection at the ACTG Pharmacology Laboratory
at the University of Alabama Birmingham [51].
Pharmacokinetic model development
A total of 2,172 plasma tenofovir determinations from 818 participants were analyzed using a non-
linear mixed-effects modeling approach (NONMEM version VII; ICON, Ellicott City, MD). One- and
two-compartment disposition models with first-order absorption were tested to determine the pharmacoki-
netic structural model. The first-order conditional estimation method with interaction (FOCE-I) was used
throughout. The final model selected was a two-compartment model that estimated the apparent oral and
intercompartmental clearances, and volumes of distribution of the central and peripheral compartments.
Because concentration data were lacking in the absorption phase, the absorption rate constant was fixed to 1
h-1 based on previous data [61]. Exponential errors with log-normal distribution were used for intersubject
variability of pharmacokinetic parameters. A proportional error model was assigned to the residual variabil-
ity. The final structural pharmacokinetic model was assessed by successful convergence and goodness-of-fit
plots. Individual Bayesian estimates of oral clearance values of tenofovir were estimated from the final
structural model.
Identifying genetic polymorphisms
Consent for DNA testing was obtained under ACTG protocol A5128 [38]. Of the 1,858 subjects with
clinical data, 1,356 consented to A5128, including 677 randomized to tenofovir-containing regimens (350
with efavirenz, 327 with atazanavir/ritonavir) and 679 randomized to abacavir-containing regimens (349
with efavirenz, 330 with atazanavir/ritonavir). Genome-wide genotype data on 1,221 subjects from the Illu-
mina Human-1M-Duo platform were available from a separate immunogenomics project [39]. The Vanderbilt
Institutional Review Boards and the ACTG approved this use of genotype data. Genetic data management
and association analyses were performed with PLINK version 1.07 [40].
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For pharmacokinetic association analyses, we considered a subset of candidate SNPs of potential relevance
to tenofovir [33-35, 41-48]. Initially, 25 candidate SNPs in 11 genes suggested to affect tenofovir renal elim-
ination were identified using the pharmGKB database (ABCB1, ABCC10, ABCC2, ABCC4, AK2, AK3,
NME1, SLC22A6, SLC22A8 and SLC22A11 ) [55]. Of the 25 SNPs, 15 were in our genotype data. Proxies
were identified for 3 of the other 10 (a total of 15 proxies) through SNP annotation and proxy (SNAP)
search [54], based on a pairwise r2 threshold of 0.8, providing a total of 30 SNPs (representing 18 candidate
SNPs) for this pharmacokinetic analysis. For separate analyses we also considered all available SNP data
between the transcription start and end positions of these 11 genes, based on the human reference genome
hg18/NCBI36 [52]. We identified 594 such SNPs: 110 in ABCB1, 12 in ABCC10, 38 in ABCC2, 378 in
ABCC4, 8 in AK2, 18 in AK3, 6 in NME1, 6 in SLC22A6, 14 in SLC22A8, 4 SLC22A11, and 0 in NME1.
For CrCl association analyses, we identified 91 SNPs previously associated with any renal phenotype at
P < 1.0 x 10−5 in any cohort, as posted to the NHGRI GWAS Catalog [49]. Trait search terms used to
survey the GWAS Catalog were ”chronic kidney disease”, ”chronic kidney disease and serum creatinine lev-
els”, ”creatinine levels”, ”end-stage renal disease”, ”glomerulosclerosis”, ”IgA nephropathy”, ”nephropathy”,
”nephropathy (idiopathic membranous)”, ”nephrotic syndrome (acquired)”, ”renal function and chronic kid-
ney disease”, ”renal function-related traits (BUN)”, ”renal function-related traits (eGRF creatinine)”, ”renal
function-related traits (sCR)” and ”renal function-related traits (urea)”. Of the 91 SNPs, 43 were available
in our genotype data. Proxies were identified for 34 of the other 48 SNPs (a total of 169 proxies) as described
above, providing a total of 212 SNPs (representing 77 candidate SNPs) for CrCl association analysis.
Quality control of genetic data
Quality control (QC) of genetic data was done using PLINK version 1.07 [40]. Before QC, 546 sub-
jects met inclusion criteria for the pharmacokinetic (1,212 for CrCl) association analyses as described in
the statistical analyses section, and with 1.2 million SNPs. We excluded subjects with greater than 2%
missing genotypes, extreme heterozygosity (|F | > 0.1), for duplicates or relatedness (pˆi > 0.125), or sex
mismatch. We excluded SNPs that deviated from Hardy-Weinberg equilibrium within principal component
(PC)-derived race/ethnicity groups (P < 10−6), with less than 98% genotyping efficiency, and minor allele
frequency (MAF) < 5%. Quality control was performed for the combined group (African Americans, Eu-
ropean Americans and Hispanic Americans, hereafter called White, Black, and Hispanic, respectively) and
separately for each race/ethnicity group.
We generated PCs to infer and adjust for genetic ancestry. Before generating PCs we removed non-
autosomal SNPs, and SNPs from two regions of high linkage disequilibrium (LD), 25.5 MB to 33.5 MB
spanning the MHC region on chromosome 6, and from 8.0 MB to 12.0 MB on chromosome 8, because these
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regions are not removed by PLINKs indep-pairwise pruning method. Subsets of SNPs in low pairwise LD
(r2 < 0.2) were used to generate PCs using smartpca in EIGENSTRAT [59]. Race/ethnicity was derived by
analyzing these samples in concert with HapMap 3 samples from 11 populations [39].
Pharmacokinetic association analyses
Pharmacokinetic association analyses included only subjects that had been randomized to tenofovir-
containing arms and had available clinical, pharmacokinetic, and genotype data. Multivariable linear regres-
sion models were fit. Analyses were performed on all subjects as a combined group, and separately in each
group (White, Black, and Hispanic) based on PCs. Meta-analysis of the three stratified models was also
performed.
Tenofovir clearance, estimated from pharmacokinetic models as described above, was regressed on geno-
type, adjusting for sex, age, body mass index (BMI), concomitant efavirenz versus atazanavir/ritonavir, and
baseline CrCl. In the combined analysis, we also adjusted for the first two PCs and self-reported race coded
as White, Black, Hispanic, and other. For QC we tested for the known genome-wide association between
UGT1A1 SNPs and baseline plasma bilirubin concentration [60].
Creatinine clearance association analyses
Creatinine clearance association analyses included subjects randomized to TDF or abacavir arms, and
with available clinical and genotype data. All determinations within 200 days after randomization were
included in analyses; 200 days was chosen as 6 months of follow-up with a grace period after looking at the
timing of creatinine measurements in the database. At least two CrCl determinations after baseline were
available from 91% of subjects.
The TDF and abacavir treatments are expected to result in different progression of creatinine clearance
over time; we were interested in identifying genes that can influence such a difference. In other words, there
is an expected interaction between treatment and time on CrCl, and we wanted to test if the interaction
differs between individuals who carry different genotypes at a genetic marker. We addressed this using a one-
degree-of-freedom test for the significance of a three-way interaction among time, treatment, and genotype.
We performed analysis using a generalized least squares regression model with compound symmetric corre-
lation structure, with creatinine clearance (hereafter called the time-dependent CrCl change) as the outcome
and including all main, two-way and three-way interactions of time, treatment arm (TDF or abacavir), and
genotype. In the model we also adjusted for sex, age, BMI, self-reported race, concomitant antiretroviral
(efavirenz or atazanavir/ritonavir), baseline CrCl, and the first two PCs. Baseline CrCl was the value at
randomization (i.e., day 0); for subjects without data on day 0, we used the first available value before
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randomization (preferred) or after randomization. Three additional models, stratified by PC-inferred race,
were fit in the same manner as above, but without adjusting for self-reported race and PCs. Meta-analysis
of regression output from the stratified models was also done. For CrCl we evaluated the 212 candidate
GWAS Catalog SNPs.
We repeated the analyses as described above, but using as a phenotype change in CrCl from baseline
to 6 months (defined as the value closest to day 183 ± 30 days). We hereafter call this the 6-month CrCl
change. This cut-off is based on reported time to change in creatinine, much of which is apparent within the
first 6 month of initiating TDF-containing regimens. Time was excluded in this model, and the p-value for
two-way interaction between genotype and treatment arm (TDF or abacavir) was calculated.
The finding from [25] suggested an interaction between TDF and atazanavir/ritonavir (ATZ/r) or
efavirenz (EFV). Therefore, we repeated the analyses for 6-month CrCl change as described above, with
the inclusion of the interaction between treatment arm and concomitant ARV. In addition, we repeated the
TDF clearance analyses as described above, but evaluated the combined effect of genotype and genotype-
EFV or ATZ/r interaction on TDF clearance using a likelihood ratio test. All analyses were repeated using
baseline plasma bilirubin concentration as a positive control phenotype.
Statistical analyses were done using PLINK version 1.07 [40] and R version 3.0.1. Meta-analyses were
performed in PLINK, and the random effects p-values reported. Analysis scripts are available upon request.
Except where indicated otherwise, we used Bonferroni correction to determine significance thresholds, with
P < 5.0× 10−8 for genome-wide analyses, and 0.05 divided by number of SNPs evaluated in each candidate
gene or SNP analysis.
Results
Study subjects and genetic data
Characteristics of subject in the tenofovir and abacavir arms are shown in Table 2. Randomization
provided similar distributions of sex, self-reported race/ethnicity, concomitant antiretrovirals, age, BMI, and
baseline creatinine clearance between arms. Subjects were predominantly male, and approximately 50%
were Black or Hispanic. Figure 1 describes data management and QC steps in the combined group analyses.
After QC, for pharmacokinetic analyses there were 501 subjects and approximately 890,000 SNPs. For
creatinine clearance analyses there were 1096 subjects (548 randomized to TDF-containing regimens) and
approximately 840,000 SNPs.
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Table 2 Baseline characteristics of participants
Variable TDF/FTC (n = 501) ABC/3TC (n = 548)
Male; No. (%) 434 (87) 472 (86)
Self-reported race/ethnicity; n (%)
White 243 (49) 243 (44)
Black 149 (30) 189 (36)
Hispanic 100 (20) 102 (18)
Other 9 (2) 14 (2)
Concomitant antiretroviral; n (%)
Atazanavir 246 (49) 269 (49)
Efavirenz 255 (51) 279 (51)
Age in years; median (IQR) 39.0 (31.0, 45.0) 38.0 (31.0, 45.0)
BMI in kg/m2; median (IQR) 24.8 (22.3, 27.9) 24.8 (22.3, 27.8)
Baseline CrCl in mL/min; median (IQR) 116.0 (99.8, 135.5) 116.6 (99.2, 138.0)
TDF/FTC = tenofovir disoproxyl fumarate with emtricitabine; ABC/3TC = abacavir with lamivudine; n = number;
kg/m2 = kilogram per square meter; mL/min = milliliter per minute; BMI = body mass index; CrCl = creatinine
clearance; IQR = interquartile range.
Pharmacokinetic association analyses
For pharmacokinetic association analyses, no SNP was significantly associated with tenofovir clearance
after Bonferroni correction. Table 3 shows the 20 SNPs with the smallest p-values in meta-analyses based
on GWAS, candidate SNPs, and candidate genes. Results of similar analyses, but for all subjects adjusting
for PC-derived ancestry, and separately within each race/ethnicity group, are provided in Appendix A.
Of 30 candidate SNPs evaluated, 15 (50%) were in ABCC4. A LocusZoom plot of this SNP position ±
500 KB was used to investigate the surrounding region. As shown in Figure 2, the SNP with the lowest p-
value in this region was in CLDN10 (rs12866697), not in ABCC4. For QC, log-transformed baseline bilirubin
concentration was analyzed as a positive control phenotype with a known genotype association [60]. Multiple
UGT1A1 SNPs were associated with baseline bilirubin (P = 2.2 x 10-11 for UGT1A1 rs887829), confirming
the ability of our analyses to detect true associations.
The analyses in which the effect of genotype and genotype-EFV or ATZ/r interaction on TDF clearance
were evaluated yielded similar results to what was initially obtained. No SNPs were genome-wide significant,
and the SNPs with the smallest p-values were the same ones seen in the initial analyses (results not shown).
Use of baseline plasma bilirubin concentration as a positive control in these analyses, again confirmed our
ability to detect true associations.
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Table 3 Meta-analysis Results of Pharmacokinetic Associations (top 20 SNPs)
GWAS Candidate SNPs (30 SNPs tested) Candidate Genes (594 SNPs tested)
SNP CHR P SNP CHR gene P SNP CHR gene P
GA032783 17 1.4e-07 rs3818486 13 ABCC4 0.03586 rs3847258 9 AK3 0.02925
rs359770 18 4.0e-06 rs2185631 6 ABCC10 0.04814 rs16921966 9 AK3 0.03278
rs359769 18 4.1e-06 rs6421690 11 SLC22A11 0.07005 rs3818486 13 ABCC4 0.03586
rs438697 1 8.2e-06 rs4148486 13 ABCC4 0.08971 rs10798924 1 AK2 0.03672
rs1833170 16 8.4e-06 rs2389204 13 ABCC4 0.107 rs12429339 13 ABCC4 0.03899
rs17199679 9 9.3e-06 rs7924450 11 SLC22A11 0.121 rs11591185 1 AK2 0.04639
rs6429839 1 1.2e-05 rs11231803 11 SLC22A11 0.1235 rs2185631 6 ABCC10 0.04814
rs4662167 1 1.2e-05 rs3818493 13 ABCC4 0.1287 rs2268691 1 AK2 0.05291
rs7829911 8 1.5e-05 rs9349256 6 ABCC10 0.1426 rs1611822 13 ABCC4 0.05928
rs1165176 6 2.0e-05 rs2274405 13 ABCC4 0.171 rs17268129 13 ABCC4 0.05975
rs1420040 16 2.0e-05 rs7331142 13 ABCC4 0.1771 rs1751033 13 ABCC4 0.07184
rs765285 6 2.1e-05 rs9524827 13 ABCC4 0.1816 rs9561765 13 ABCC4 0.07938
rs1165177 6 2.1e-05 rs9394952 6 ABCC10 0.2 rs1564351 13 ABCC4 0.08005
rs1185569 6 2.1e-05 rs1045642 7 ABCB1 0.2381 rs7330330 13 ABCC4 0.08221
rs4319926 2 2.2e-05 rs2273697 10 ABCC2 0.2803 rs4148487 13 ABCC4 0.08363
rs4442993 2 2.2e-05 rs717620 10 ABCC2 0.2872 rs4148442 13 ABCC4 0.08676
rs563189 1 2.5e-05 rs2125739 6 ABCC10 0.3188 rs4148451 13 ABCC4 0.08676
rs10503961 8 2.5e-05 rs4148477 13 ABCC4 0.3348 rs1729745 13 ABCC4 0.08888
rs7144413 14 2.7e-05 rs4148478 13 0.3348 rs4148486 13 ABCC4 0.08971
rs11844480 14 2.8e-05 rs17222723 10 0.4265 rs9524858 13 ABCC4 0.09165
CHR = Chromosome; SNP = SNP identifier; P = P-value. Significance levels were approximately 5 × 10−8 for the
genome-wide analyses, 0.002 for the subset of 30 SNPs and 8.4× 10−5 for the subset of 594 SNPs.
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Figure 1 Disposition of study subjects and SNPs through the data management and QC process. Top panel is the
disposition of study subjects. The number of subjects included in PK and CrCl association analyses varied depending
on the SNPs included in the analysis, with a median (IQR) of 501 (500 to 501) PK analysis subjects, and 1039 (1038
to 1040) CrCl analysis subjects. Bottom panel is the disposition of genetic polymorphisms.
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Figure 2 LocusZoom plot of ABCC4 gene region for association with tenofovir pharmacokinetics by meta- analysis.
The region of ABCC4 (±500 KB) is shown. Genes in the region are shown at the bottom. Filled circles represent
p-values for SNPs in our data. The lowest p-value SNP in this region, rs12866697, is represented by the purple
diamond. Markers are color coded to represent their degree of correlation (r2) with rs12866697 as estimated internally
by LocusZoom using the hg18/HapMap Phase II CEU genome build. The blue lines correspond to the recombination
rate [56].
Creatinine clearance association analyses
In the time-dependent CrCl change analyses, no SNP was significantly associated after Bonferroni
correction. The 20 SNPs with the lowest p-values in GWAS and candidate SNP meta-analyses are shown in
Table 4. Results of similar analyses, but for all subjects adjusting for PC-derived ancestry, and separately
within each race/ethnicity group, are provided in Appendix A.
In the analysis involving the entire population, rs1751036 in ABCC4 was among the top 20 SNPs for
time-dependent CrCl change (P = 2.4 × 10−5, Table 13). A LocusZoom plot of the ABCC4 region (± 500
KB) is shown in Figure 3. Twelve ABCC4 SNPs in LD with rs1751036 at r2 > 0.8 were associated with
time-dependent change in creatinine clearance at unadjusted P < 0.01, and are listed in the figure legend.
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Table 4 Meta-analysis Results of Creatinine Clearance Associations (top 20 SNPs)
GWAS Candidate SNPs (from GWAS catalogue)
SNP CHR P SNP CHR Gene P
rs121882 5 1.24e-05 rs10941692 5 Intergenic 0.02643
rs4243086 15 1.45e-05 rs7805747 7 PRKAG2 0.02802
rs9602954 13 1.51e-05 rs12520150 5 Intergenic 0.04025
rs3914576 15 1.96e-05 rs9473932 6 Intergenic 0.05142
rs419129 6 2.54e-05 rs2082424 19 CEP89 0.05577
rs17039196 4 2.91e-05 rs7246178 19 CEP89 0.05923
rs17622266 7 3.03e-05 rs660895 6 Intergenic 0.07165
rs6963950 7 3.04e-05 rs17272197 19 SLC7A9 0.147
rs7002294 8 3.97e-05 rs1133029 20 Intergenic 0.1493
rs7034027 9 4.21e-05 rs653178 12 ATXN2 0.1501
rs2273289 1 4.32e-05 rs2057291 20 GNAS 0.1516
rs10758871 9 4.45e-05 rs6677604 1 CFH 0.1602
rs1976756 15 4.54e-05 rs4664308 2 PLA2R1 0.2388
rs7033976 9 4.57e-05 rs16902083 5 HCN1 0.2478
rs3750494 9 4.69e-05 rs11705804 3 Intergenic 0.2497
rs749074 14 5.54e-05 rs1556751 9 PIP5K1B 0.2523
rs4524177 20 5.61e-05 rs11864909 16 PDILT 0.2545
rs2682621 12 5.92e-05 rs3925075 16 Intergenic 0.2577
rs11067378 12 6.43e-05 rs16853741 3 MECOM 0.2661
rs12701851 7 6.65e-05 rs2151421 9 PIP5K1B 0.2759
Significance levels: approximately 5×10−8 for GWAS; 0.0002 for the subset of 212 SNPs.
In analyses by population, among African Americans, considering 6-month CrCl change, rs3127573 in
SLC22A2 was associated in the candidate SNPs analysis (Table 14, P = 3.3×10−5), and was also among the
top 20 SNPs in the genome-wide analysis (Table 14). This SNP had the second lowest P-value (P = 0.0018)
among African Americans in the analysis of the 212 candidate SNPs with time-dependent CrCl change
(Table 13), and was among the top 20 SNPs in the 212 candidate SNPs analysis of the combined group with
time-dependent CrCl change (Table 13, P = 0.09), and in the genome-wide analysis of combined group with
6-month CrCl change (Table 14, P = 0.036).
The analyses of 6-month CrCl change in which the interaction between treatment arm and EFV or ATZ/r
was included yielded fairly similar results to those in which this interaction was not included. Except for the
same SNP (rs3127573, P = 4.1× 10−5) in the 212 candidate SNPs analysis of the African American group,
no polymorphisms were significantly associated with the outcome.
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Figure 3 LocusZoom plot of ABCC4 gene region for association with change in creatinine clearance in the entire
population. The region of ABCC4 (±500 KB) is shown. Genes in the region are shown at the bottom. Filled circles
represent p-values for SNPs in our data. The lowest p-value SNP in this region, rs1751036, is represented by the
purple diamond. Markers are color coded to represent their degree of correlation (r2) with rs1751036 as estimated
internally by LocusZoom using the hg18/HapMap Phase II CEU genome build [56]. The 12 SNPs with the lowest
p-values are rs7330330, rs7331488, rs4148540, rs2766475, rs1678387, rs1678409, rs1678365, rs1189466, rs1751043,
rs943289, rs1189435, and rs1189434.
Discussion
Tenofovir disoproxil fumarate is one of the most extensively prescribed antiretroviral drugs worldwide.
The present report describes the first GWAS to investigate associations with tenofovir pharmacokinetics,
and the first GWAS to investigate change in CrCl with tenofovir-containing regimens. No polymorphism
achieved genome-wide significance (P < 5.0×10−8) for association with either tenofovir clearance or change
in CrCl. The tenofovir clearance GWAS was complemented by targeted analyses involving 594 SNPs in
genes suggested to affect tenofovir disposition, and an even more focused analysis involving 30 candidate
SNPs suggested to affect tenofovir disposition. No polymorphism was significant in either of these analyses.
Our CrCl GWAS was complemented by a more targeted analyses of 212 SNPs associated with any renal
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trait in prior GWAS. Again, no polymorphism was significant in these targeted analyses.
Several aspects of the present study should have favored our likelihood of identifying true-genotype-
phenotype associations if present. Both CrCl and tenofovir clearance analysis involved over 500 subjects,
far more than were studied in previous genetic association studies of tenofovir renal toxicity [33-35, 43].
The extent of genotype data analyzed far exceeded previous candidate gene analyses [33-35, 43]. Clinical
data were from a prospective, randomized clinical trial, which included rigorous quantification of change
in creatinine clearance over time, and which showed TDF/emtricitabine with atazanavir/ritonavir to be
less favorable in this regard [25, 60, 62]. For CrCl analyses, availability of well matched randomized arms
that included abacavir (which is not nephrotoxic) rather than TDF provided leverage to identify genetic
associations specific to tenofovir. Substantial numbers of White, Black and Hispanic subjects afforded the
opportunity to examine associations both in the combined population, and in each population separately,
an approach that has proven valuable in pharmacogenomic analyses of other antiretroviral drugs [60, 62].
Longitudinal models used in our analyses allowed us to capture associations between genotype and change
in CrCl over time.
There are several possible reasons for the lack of significant association in the present analyses. With
GWAS the threshold for significance after correcting for multiple comparisons is very stringent. However,
functional polymorphisms that affect drug disposition and/or pharmacodynamics may be genome-wide signif-
icant with modest sample sizes. For example, genetic prediction of abacavir hypersensitivity is genome-wide
significant (P < 5.0 × 10−8) with 15 cases and 200 controls [63] and statin response with 85 cases and 90
controls [64]. In addition, we complemented our GWAS with more focused candidate gene/SNPs analyses
with less stringent P-value thresholds, which still did not identify significant associations. It is possible that
effects of genetic polymorphisms are context dependent, such that they may not have been detected with
concomitant efavirenz or atazanavir/ritonavir (the analyses with the EFV or ATZ/r interactions also showed
insufficient evidence that the effect of genotype on tenofovir clearance or 6-month CrCl change differed by the
EFV or ATZ/r), but could have been apparent with other concomitant antiretrovirals. We cannot exclude
the possibility that previously reported associations were spurious, as reported P-values were marginally sig-
nificant and would not have withstood correction for multiple comparisons even for the few SNPs genotyped.
We considered plasma tenofovir clearance as a phenotype in the present analyses, despite intracellular
tenofovir diphosphate being the presumed toxic moiety. Our primary rationale for studying plasma tenofovir
clearance was the hypothesis that functional drug transporter gene polymorphisms that affect drug dispo-
sition across cell membranes would likely also affect plasma drug concentrations. The lack of significant
genetic associations with plasma tenofovir clearance thus reinforces the lack of associations with CrCl.
Within each analysis, there was some overlap for a few SNPs, especially in the combined and meta-
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analyses. Although not significant, most of the top SNPs in pharmacokinetic candidate SNP analyses were
in ABCC genes , which have been shown to play a role in mechanisms of tenofovir clearance and creatinine
clearance among patients receiving tenofovir [31-35]. A previous study of the association of ABCC10 poly-
morphisms with kidney tubular dysfunction (KTD) identified an association between rs9349256 (odds ratio
= 2.3, P = 0.02) and rs2125739 (OR = 2.0, P = 0.05) and tubular dysfunction [35]. In our study, rs9349256
was among the top 20 (of 30) candidate SNPs evaluated in the combined, African American and European
group analyses, and was among the top 20 (of 594) candidate SNPs evaluated in the European population
(P = 0.10), which also suggests the potential role of this SNP in tenofovir clearance.
Although none of the SNPs in the ABCC family were significant at the genome-wide or candidate SNP
level, a SNP near ABCC4, rs12866697 located in CLDN10, was the top SNP in the ABCC4 region (± 500
KB). A biological study in mice linked loss of CLDN10 to hypermagnesemia and nephrocalcinosis because
this gene is involved in paracellular sodium permeability [57], but the relevance of this to tenofovir is not
apparent.
Only the sensitivity analysis of the 212 candidate SNPs identified SNP rs3127573 as being significant in
the CrCl associations. However, this SNP appeared among the top 20 SNPs in some of our genome-wide
and candidate SNPs analyses as outlined in the results section. Previous studies have shown the potential
role played by SLC22A6 and SLC22A7 in the renal proximal tubules [32, 46]. Furthermore, a study of the
association of SLC22A2 polymorphisms with phenotypes of net tubular creatinine secretion in which SNP
rs3127573 was one of the two SNPs genotyped in patients with end-stage renal disease found a positive asso-
ciation between end-stage renal disease and SNP rs3127573: odds ratios [95% CI] 1.39 [1.16-1.67] [58]. Our
results are in the same direction as this finding and hence affirm the association of some SNPs in SLC22A2
with renal phenotypes.
There were limitations to the present study. Renal toxicity associated with tenofovir in A5202 was mod-
est, so did not include subjects representing extreme phenotypes. The present analysis focused on change
in CrCl as the primary phenotype, but it is possible that other markers of renal tubular function are more
affected by genotype. The sample size within each PC-derived race/ethnicity was small, although studies
have reported significance with even fewer individuals [33-35].
In summary, we did not identify significant genetic associations with plasma tenofovir clearance of change
in CrCl among patient randomized to TDF-containing regimens in A5202. Further research is warranted to
determine whether previously suggested genetic associations with tenofovir-associated renal tubular injury
depend on context, such as specific concomitant medication.
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CHAPTER III
New Method: Residual-based Conditional Continuous by Ordinal
Test (CoCoBOT)
Motivation
Some of the previously discussed methods for analysis of ordinal data either assume linearity, or ignore
order information of the categorical variable. On the other hand, the residual-based CoCoBOT method
allows a monotone relationship between a continuous outcome (Y) and an ordered categorical predictor (X),
after adjusting for other covariates (Z) that can be continuous or categorical. This is accomplished by fitting
separate regression models of Y on Z (e.g. linear regression), and X on Z (e.g. proportional odds) and then
a residual-based test statistic is constructed. Specifically, the correlation between probability-scale residuals
from the two models is assessed. In the subsections that follow, we develop the theory of residual-based
CoCoBOT by adapting the methods for the second test statistic described in the COBOT paper by Li
and Shepherd [9]. From COBOT, given an ordinal outcome, Y, an ordinal predictor, X and covariates, Z,
the residual-based test statistic is constructed by fitting the models for P (Y |Z) and P (X|Z), obtaining the
residuals from each, i.e., Yi,res and Xi,res, respectively, and then testing for the correlation between Yi,res
and Xi,res.
Basic Theory
Definition of Residual For an Ordinal Outcome
Suppose an individual has an observed outcome Y = y and inputs Z = z. A linear regression of Y on
Z produces the fitted value, yˆ = E(Y |z). The observed minus expected residual is defined as the difference
between the observed response value, y, and the predicted value, yˆ, i.e., (y − yˆ). The development of the
residual for an ordered categorical outcome, X, is based on the definition of the residual from linear regression
as the expectation of a random variable, (x−Xfit), where Xfit ∼ X|z, and X|z is the distribution of possible
outcome values given z. Since it is not possible to calculate E(x−Xfit) when X is an ordinal variable (with
s categories), for an individual i with outcome Xi = xi, it is plausible to compare xi and Xi,fit with respect
to whether xi is at a lower or higher level than Xi,fit. The probability for xi to be higher than Xi,fit is
pi,high = P (xi > Xi,fit) = γ
xi−1
i , where γ
j
i = P (X ≤ j|Zi = zi), for j = 1, . . . , s. The probability for xi
to be lower than Xi,fit is pi,low = P (xi < Xi,fit) = 1 − γxii . The probability for xi to tie with Xi,fit is
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P (xi = Xi,fit) = p
xi
i . Scores are then assigned to these three events such that 1 = higher, -1 = lower, and 0
= tie. The expected score, Xi,res = pi,high− pi,low, is a function of data (Xi,Zi) and model parameters θX .
Definition of Test Statistic
In this setting, the outcome, Y is continuous while the predictor X is ordinal. Therefore, for subject i,
the observed minus expected residuals from the model for P (Y |Z) is Ryi = E(yi − Yi,fit). The probability-
scale residuals can be determined by either assuming a normal distribution or empirically; we show how
the residuals can be estimated empirically. Define F (Ryi ) =
1
n
n∑
j=1
I(Ryj ≤ Ryi ) as the empirical cumulative
distribution function (cdf) of the Ryj ’s. Assuming A ∼ F , the residual for individual i, of a similar form to
that described above for ordinal outcomes, is thus defined as:
Yi,res = PF (A < R
y
i )− PF (A > Ryi )
= PF (A < R
y
i )− (1− PF (A ≤ Ryi ))
= 2
1
n
n∑
j=1
I(A ≤ Ryi )−
1
n
n∑
j=1
I(A = Ryi )− 1
= 2F (Ryi )−
1
n
n∑
j=1
I(A = Ryi )− 1.
On the other hand the residual from the model for P (X|Z) is defined as described above for an ordinal
outcome, i.e., for a fitted model with parameter estimates θˆ
X
, the residual for subject i is defined as
xi,res = Xi,res|θˆX . The residual-based test statistic is defined as:
T = cor(Yres, Xres)
=
cov(Yres, Xres)√
var(Yres)var(Xres)
Under the null, the conditional distributions of Y and X given Z are independent, in which case
cov(Yres, Xres) = 0 and subsequently, T = 0. Under the null, Tˆ converges to zero as the sample size
goes to infinity.
Determination of P-value For Test Statistic
Two approaches for obtaining the distribution of the test statistic, T , defined above are described in detail
in Li and Shepherd [9]. They describe an empirical approach and a large sample approximation for obtaining
the distribution of Tˆ , and show via simulation studies that under correctly specified models, high power is
achieved regardless of which approach is used to compute the p-value for the test statistic. For our study,
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we will use the large sample approximation approach to determine the p-value for T . Briefly, the asymptotic
distribution approach relies on the M-estimation method [12], in which estimates of a vector of p parameters,
θ, are obtained by finding the solution to the vector equation
n∑
i=1
Ψi(θ) = 0, where Ψi = Ψ(Yi, Xi,Zi;θ), is
a (p x 1)-function that does not depend on i or n. Provided Ψi(θ) is sufficiently smooth, i.e., has continuous
derivatives up to some desired order over some domain, and θ has fixed dimension, as n −→ ∞,
√
n(θˆ − θ) d−→ N(0, V (θ)),
where V (θ) = A(θ)−1B(θ)[A(θ)−1]′, A(θ) = E[− ∂∂θΨi(θ)], and B(θ) = E[Ψi(θ)Ψi(θ)′]. If T = g(θˆ) is a
smooth function of θˆ, then from the delta method,
√
n[g(θˆ)− g(θ)] d−→ N(0, σ2),
where σ2 = [ ∂∂θg(θ)]V (θ)[
∂
∂θg(θ)]
′. The estimators of A(θ), B(θ) and ∂∂θg(θ) are:
Â(θ) =
1
n
n∑
i=1
[− ∂
∂θ
Ψi(θˆ)],
B̂(θ) =
1
n
n∑
i=1
[Ψi(θˆ)Ψi(θˆ)
′],
∂̂
∂θ
g(θ) =
∂
∂θ
g(θˆ).
Under the null, if g(θ) = 0, the p-value can be approximated as 2Φ
(−|T |
σˆ
√
n
)
, where Φ is the cdf of the standard
normal distribution.
Definition of Estimating Function, Ψ(θ)
We now define the estimating equations used to calculate the p-value described in the previous subsection.
The parameter vector, θ, has the form, θ = (θY ,θX ,θT ), where θT is the parameter vector for the residual-
based test statistic. The resultant estimating function, Ψ(Yi, Xi,Zi;θ) has the form:
Ψi(θ) =

Yi −ZiθY
(Yi −ZiθY )Zi
d
dθX
lX(Xi,Zi;θ
X)
ψ(Yi, Xi,Zi;θ
T )
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where Ziθ
Y = Yi,fit, the fitted value from a linear model with parameters θ
Y and lX is the log-likelihood
function of the model for P (X|Z), with parameters θX . E[ d
dθX
lX(Xi,Zi;θ
X)] = 0, since it is the ex-
pected value of a score function. θT = (w1, w2, w3, w4, w5), where w1 = E(Yi,res), w2 = E(Xi,res),
w3 = E(Yi,resXi,res), w4 = E(Y
2
i,res) and w5 = E(X
2
i,res). The resultant estimating function is:
ψ(Yi, Xi,Zi;θ
T ) =

Yi,res − w1
Xi,res − w2
Yi,resXi,res − w3
Y 2i,res − w4
X2i,res − w5
Solving the equation
n∑
i=1
ψ(Yi, Xi,Zi;θ
T ) = 0, we have wˆ1 =
1
n
n∑
i=1
yi,res, wˆ2 =
1
n
n∑
i=1
xi,res,
wˆ3 =
1
n
n∑
i=1
yi,resxi,res, wˆ4 =
1
n
n∑
i=1
y2i,res and wˆ5 =
1
n
n∑
i=1
x2i,res. Let g(θ) = cor(Yi,res, Xi,res) =
E(Yi,resXi,res)−E(Yi,res)E(Xi,res)√
E[Y 2i,res−(EYi,res)2]E[X2i,res−(EXi,res)2]
= w3−w1w2√
(w4−w21)(w5−w22)
. Then, under the null, g(θ) = 0 and T = g(θˆ).
Given g(θ) = (w3 − w1w2) ×
[
(w4 − w21)(w5 − w22)
]−1/2
= num × den, the partial derivatives for g(θ) are
defined as follows:
d
dw1
g(θ) = −w2den− 1
2
num× den3(−2w1(w5 − w22)
d
dw2
g(θ) = −w1den− 1
2
num× den3(−2w2(w4 − w21))
d
dw3
g(θ) = den
d
dw4
g(θ) = −1
2
num× den3(w5 − w22)
d
dw5
g(θ) = −1
2
num× den3(w4 − w21)
Simulation Study
In this section, we simulate data to evaluate the performance of the residual-based CoCoBOT method,
additive, dominant, and recessive models under different data generation specifications, and compare and
contrast finding. Two sets of simulations are performed; in the first one, Z is generated conditioned on X
and in the second one, X is generated conditioned on Z using the proportinal odds model.
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Methods
Data were generated under five gene models including additive, dominant, recessive and two non-linear
gene models. The analysis with CoCoBOT involves fitting a proportional odds (PO) model of X|Z in order
to calculate the probability-scale residuals. In the first simulation, we generated Z|X and then fit a model
of X|Z using PO model. To ensure our Silumation 1 results were not affected by model misspecification,
we repeated simulation 2, in which we generated X|Z under the PO model and then fit the a PO model of
X|Z. Datasets of size N=500 were generated in the following manner:
• Simulation 1:
– Genotype, X (0, 1, or 2) was generated under Hardy-Weinberg equilibrium (HWE),
that is, from a multinomial distribution with expected genotype probabilities,
P (aa) = p2, P (AA) = q2 and P (Aa) = 2pq, where q = 1 − p, and p represents
the minor allele frequency (MAF) and was set to 0.5, 0.3, 0.1 or 0.05. The minor
allele is denoted with a and the major allele denoted by A.
– Z was generated from N(0.5X, 4).
– The phenotype Y was drawn from N(1 + ηf(X) + 0.5Z, 1). ηf(X) specifies the
relationship between the number of alleles and the phenotype, and was set to be one
of the following for X = 0, 1, 2:
∗ Additive, f(X) = X; η = 0.2
∗ Dominant; f(X) = 0, 1, 1; η = 0.3
∗ Recessive; f(X) = 0, 0, 1; η = 0.3
∗ Non-linear 1; f(X) = 0, 1, 4; η = 0.1
∗ Non-linear 2; f(X) = 0, 3, 4; η = 0.1
• Simulation 2:
– Z was generated from N(0, 1).
– Genotype, X (0, 1, or 2) was generated from a proportional odds model such that
P (X ≤ j|Z) = [1+exp(−(αX +βXZ))]−1 for j = 1, . . . , 3. For each data generation,
the values of αX and βX were adjusted accordingly to attain MAFs of 0.5, 0.3, 0.1
and 0.05.
– The phenotype Y was drawn from N(1 + ηf(X) + 0.5Z, 1), with ηf(X) specified as
in Simulation 1 above except for the recessive model, η was set to 0.4 instead of 0.3.
To each dataset, we fit a linear regression model including Z and X and assuming the relationship between
X and Y conditional on Z was one of the following:
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• Additive; linear relationship
• Dominant; X dichotomized with X = 1, 2 put in the same group
• Recessive; X dichotomized with X = 0, 1 put in the same group
• Categorical; X treated as categorical variable
Finally, analysis using the new approach (residual-based CoCoBOT) was performed, fitting a linear model
of Y on Z, a proportional odds model of X on Z, and assessing the correlation between the probability-scale
residuals. This was done for each of 1000 simulation replications. Power was compared by computing the
proportion of simulation replications that found an association between Y and X conditional on Z with
p-value < 0.05.
Results
Simulation 1 results are presented in Table 5. With data generated using an additive model, the residual-
based CoCoBOT approach was only slightly less powerful than the properly specified additive model. The
CoCoBOT model was slightly more powerful than the categorical and dominant models, and easily out-
performed the recessive model at minor allele frequencies < 0.5. On the other hand, with data generated
using the dominant model, the CoCoBOT approach was less powerful than the properly specified dominant
model, and outperformed the recessive model specification that had the lowest power among all five models.
The categorical model performed better than CoCoBOT at MAF = 0.5, and was almost as good as the
CoCoBOT and additive models at MAF < 0.5. CoCoBOT was slightly more powerful than the additive
model but there was no clear winner between the two under this setting.
As expected, the CoCoBOT model was outperformed by the recessive model when data was generated
using a recessive model. The categorical model performed better than the CoCoBOT, additive and dom-
inant models under this setting; CoCoBOT outperformed the dominant model and was only slightly less
powerful than the additive model. With data generated under the non-linear 1 model, the CoCoBOT model
performed better than the dominant and categorical models at MAF = 0.5. However, the additive model
was the winner at MAF < 0.5. With data generated under the non-linear 2 model, the CoCoBOT model
was generally better than the recessive model, fairly similar to the additive model, and slightly worse than
the dominant model. Results for data generated under the recessive and non-linear 1 models tended to be
similar because the form of the basis function is comparable; (0,0,1) and (0,1,4) respectively. Likewise, the
results for data generated under the dominant and non-linear 2 models were fairly similar because the form
of the basis function is comparable; (0,1,1) and (0,3,4) respectively.
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Table 5 Power of Estimators to Detect Genetic Associations: Z|X generated from multinomial distribution
Data Generation Model Analysis Model Minor Allele Frequency(p)
0.5 0.3 0.1 0.05
Additive CoCoBOT 0.848 0.783 0.447 0.286
(0,1,2) Additive 0.867 0.811 0.478 0.283
Dominant 0.72 0.717 0.457 0.287
Recessive 0.723 0.475 0.13 0.074
Categorical 0.804 0.725 0.378 0.244
Dominant CoCoBOT 0.638 0.881 0.73 0.484
(0,1,1) Additive 0.661 0.865 0.722 0.483
Dominant 0.817 0.917 0.754 0.503
Recessive 0.142 0.174 0.084 0.074
Categorical 0.735 0.86 0.652 0.451
Recessive CoCoBOT 0.616 0.182 0.052 0.047
(0,0,1) Additive 0.629 0.261 0.06 0.053
Dominant 0.144 0.096 0.052 0.049
Recessive 0.816 0.471 0.095 0.073
Categorical 0.723 0.378 0.067 0.06
Non-linear 1 CoCoBOT 0.86 0.536 0.183 0.128
(0,1,4) Additive 0.882 0.616 0.22 0.131
Dominant 0.481 0.379 0.187 0.121
Recessive 0.903 0.612 0.142 0.079
Categorical 0.849 0.599 0.189 0.113
Non-linear 2 CoCoBOT 0.879 0.921 0.767 0.528
(0,3,4) Additive 0.89 0.918 0.765 0.535
Dominant 0.892 0.933 0.772 0.537
Recessive 0.474 0.355 0.114 0.072
Categorical 0.865 0.886 0.686 0.465
Table 6 shows the results from Simulation 2 in which genotype data was generated under the PO model.
Except for the difference in the actual values observed, the results are similar to those obtained from Sim-
ulation 1; for instance, with data generated under the additive model, the additive model had the highest
power; CoCoBOT was slightly less powerful than the additive model, and the recessive model had the lowest
power. In addition, under the nonlinear 1 data generation setting, the additive model had the highest power
at MAF < 0.5 but was not much better than CoCoBOT which had similar power.
Based on the simulation results, low power is generally observed under low minor allele frequencies
(≤ 0.1), in which the probability of the a/a genotype is (≤ 0.01). This is evident especially for the recessive
and non-linear 1 data generation models, in which most of the effect of the genotype is due to the ”a” allele,
and thus power is low for all analysis models.
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Table 6 Power of Estimators to Detect Genetic Associations: X|Z generated under a PO model
Data Generation Model Analysis Model Minor Allele Frequency(p)
0.5 0.3 0.1 0.05
Additive CoCoBOT 0.637 0.803 0.447 0.349
(0,1,2) Additive 0.656 0.834 0.478 0.354
Dominant 0.361 0.744 0.464 0.347
Recessive 0.437 0.518 0.107 0.11
Categorical 0.548 0.756 0.392 0.288
Dominant CoCoBOT 0.373 0.815 0.749 0.45
(0,1,1) Additive 0.4 0.795 0.769 0.442
Dominant 0.642 0.874 0.774 0.464
Recessive 0.077 0.117 0.082 0.073
Categorical 0.532 0.797 0.691 0.389
Recessive CoCoBOT 0.177 0.111 0.07 0.058
(0,0,1) Additive 0.196 0.139 0.093 0.057
Dominant 0.047 0.06 0.058 0.048
Recessive 0.316 0.249 0.156 0.084
Categorical 0.237 0.201 0.124 0.064
Non-linear 1 CoCoBOT 0.579 0.489 0.27 0.187
(0,1,4) Additive 0.631 0.574 0.343 0.246
Dominant 0.145 0.335 0.266 0.184
Recessive 0.676 0.556 0.31 0.207
Categorical 0.614 0.526 0.314 0.202
Non-linear 2 CoCoBOT 0.672 0.943 0.742 0.49
(0,3,4) Additive 0.692 0.938 0.746 0.482
Dominant 0.707 0.944 0.75 0.512
Recessive 0.171 0.351 0.19 0.202
Categorical 0.664 0.903 0.654 0.419
Discussion
In conclusion, the CoCoBOT method does not appear to be generally robust for genetic association
studies. It seems to struggle particularly under the recessive data generation scenario - the effect here is
mainly driven by the a/a genotype, and the probability of observing this genotype is generally low, resulting
in low power to detect associations. Except under the truth, the CoCoBOT approach easily outperforms the
recessive and dominant models. Thus, a priori knowledge should drive the selection of either the dominant
or recessive models; otherwise, model misspecifications can lead to significant loss of detection power.
Although CoCoBOT’s performance is fairly similar to that of the additive model, the additive model
seems to be more robust for genetic data analysis, especially since in real data settings, the data generation
model is unknown. The categorical approach generally performs well even in nonlinear scenarios, and in
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addition to the additive model, might also be a good choice for detection of SNPs. The low power under low
MAF’s however, does not seem to be dependent on the analysis model chosen; it is potentially due to the
small probability of observing the genotype that is contributing to most of the effect. Finally, the results
from Simulation 2, in which genotype was generated under the proportional odds model, suggest that our
results from Simulation 1 were not driven by model misspecification since the two simulations led to similar
conclusions about the performance of the five methods.
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CHAPTER IV
Case Study
In this chapter, we use the ACTG data (introduced and used in Chapter II) to compare the performance
of the five analysis models described in Chapter III. We focus on detection of SNPs associated with the two
outcomes, tenofovir clearance and 6-month creatinine clearance (CrCl) change, both described in Chapter
II. Detailed descriptions of the study subjects, tenofovir assays and plasma sampling procedures, pharma-
cokinetic model development and quality control of genetic data are given in the Methods section of Chapter
II. For all statistical analyses, PLINK version 1.07 and R version 3.0.1 were used. Bonferroni correction was
used to determine significance thresholds, with P < 5.0× 10−8 for genome-wide analyses.
Methods
Tenofovir pharmacokinetic association analyses
Pharmacokinetic analyses of tenofovir clearance included only subjects that had been randomized to
tenofovir-containing arms and had available clinical, pharmacokinetic, and genotype data. Analyses were
performed on all subjects, and then separately based on PC-derived race (White, Black, and Hispanic).
For each analysis, five multivariable regression models were fit using tenofovir (TDF) clearance as the
primary outcome (Y ), genotype as the main predictor (X) modeled with additive, dominant, recessive, cate-
gorical and CoCoBOT models. All models were adjusted for sex, age, body mass index (BMI), concomitant
efavirenz versus atazanavir/ritonavir, and baseline CrCl. In the combined analysis, we also adjusted for the
first two PCs and self-reported race/ethnicity coded as White, Black, Hispanic, and other. We also tested
for known genome-wide association between UGT1A1 SNPs and baseline plasma bilirubin concentration.
Creatinine clearance association analyses
The analyses in this subsection included subjects randomized to TDF and abacavir arms, and with
available clinical and genotype data. For each analysis, multivariable regression models were fit using the
additive, dominant, recessive, categorical and CoCoBOT model specifications. In the analysis of all subjects,
6-month CrCl change, defined in Chapter II, was regressed on genotype and all models were adjusted for sex,
age, BMI, self-reported race, concomitant antiretroviral (efavirenz or atazanavir/ritonavir), baseline CrCl,
and the first two PCs.
Three additional models stratified by PC-inferred race were separately fit using each of the five model
specifications; 6-month CrCl change was regressed on similar variables as in the analysis of all subjects,
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with the exclusion of self-reported race and PCs from the models. For quality control, all analyses involving
subjects randomized to TDF and abacavir were repeated as described above but using baseline plasma
bilirubin as the outcome.
Results
Table 2 shows a detailed summary of study participants’ baseline characteristics, and Figure 1 shows a
summary of the data management and QC steps employed in the dataset containing all individuals regardless
of race/ethnicity. For the TDF pharmacokinetic association analyses, 501 individuals and approximately
890,000 SNPs were included. For creatinine clearance association analyses there were 1039 subjects and
approximately 840,000 SNPs.
Tenofovir pharmacokinetic association analyses
Table 7 shows a pairwise correlation matrix of p-values from the combined group analyses under the
five different analysis models. There is a strong correlation of p-values between CoCoBOT and the additive
model (ρ = 0.801); CoCoBOT is also strongly correlated with the dominant model (ρ = 0.709) but has low
correlation with the recessive model (ρ = 0.204).
Table 7 TDF clearance: Correlation matrix of p-values from combined group analysis
CoCoBOT Additive Dominant Recessive Categorical
CoCoBOT 1
Additive 0.801 1
Dominant 0.709 0.733 1
Recessive 0.204 0.326 0.067 1
Categorical 0.557 0.648 0.643 0.653 1
The categorical model seems to be fairly correlated with the additive, recessive and dominant models
(ρ ≈ 0.650), but slightly less with CoCoBOT. A very similar pattern of correlation was observed (not
shown) in the models stratified by PC-inferred race/ethnicity (African American, Europeans, Hispanics).
Quality control analyses with bilirubin as the outcome also yielded results with a similar pattern; Table 16
of Appendix B shows the correlation matrix from the analysis of all subjects.
Table 8 shows the 10 SNPs with the smallest p-values in combined group analysis under each of the
five analysis models. The first 4 (3) SNPs in the recessive (categorical) model were genowe-wide significant.
Furthermore, three of the SNPs (rs12082252, rs337298, rs16823145), all in chromosome 1, were similar
between the two model specifications.
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Table 8 TDF clearance: SNPs with the smallest p-values in combined group analysis
CoCoBOT Additive Dominant Recessive Categorical
CHR SNP P CHR SNP P CHR SNP P CHR SNP P CHR SNP P
23 rs12387850 2.80e-07 23 rs12387850 1.26e-06 23 rs12387850 5.63e-07 1 rs12082252 2.28e-10 1 rs337298 7.80e-10
6 rs1141034 2.63e-06 17 GA032783 2.14e-06 19 rs3815748 5.17e-06 1 rs337298 7.58e-10 1 rs12082252 1.69e-09
3 rs4688755 4.28e-06 18 rs4891230 6.46e-06 5 rs6878929 6.96e-06 1 rs16823145 3.01e-08 1 rs16823145 4.87e-08
23 rs6653311 4.88e-06 18 rs9950415 6.76e-06 16 rs12929434 7.09e-06 19 rs263053 4.27e-08 17 GA032783 8.75e-08
3 rs2883057 4.92e-06 9 rs2478851 9.58e-06 4 rs11723812 7.41e-06 3 rs854207 1.51e-07 19 rs263053 3.02e-07
3 rs4688690 4.92e-06 1 rs11165778 9.59e-06 6 rs1141034 8.05e-06 18 rs966634 3.28e-07 9 rs7849259 4.91e-07
3 rs2526751 4.92e-06 13 rs8001616 9.66e-06 15 rs12440239 1.00e-05 1 rs6695258 3.85e-07 1 rs6695258 5.76e-07
3 rs9311446 4.92e-06 4 rs11723812 1.19e-05 14 rs7144413 1.14e-05 21 rs9982266 4.80e-07 2 rs12479145 6.08e-07
11 rs12420080 4.92e-06 2 rs1375178 1.27e-05 4 rs7687008 1.26e-05 1 rs4391664 5.11e-07 1 rs17641977 6.69e-07
3 rs4688758 5.04e-06 17 rs199529 1.41e-05 17 rs1230103 1.65e-05 3 rs1469386 5.14e-07 9 rs11791293 6.81e-07
Table 9 shows the ranks of the unique SNPs from Table 8 under each analysis model, and their respective
p-values. SNP rs12387850 was ranked first in the CoCoBOT (P = 2.80× 10−7), additive (P = 1.26× 10−6)
and dominant models (P = 5.63× 10−7), but ranked the 75th (P = 1.07× 10−5) and 26th (P = 3.71× 10−6)
in the recessive and categorical models respectively. Among the SNPs significantly associated with tenofovir
clearance, SNP rs12082252 ranked 1st (P = 2.28 × 10−10) and 2nd (P = 1.69 × 10−9) in the recessive and
categorical models respectively, but was ranked much lower in the other model specifications (346688th in
CoCoBOT, 1924th in additive, 90918th in dominant).
Results of similar analyses (top SNPs), but separately within each race/ethnicity, are provided in Ap-
pendix B Tables 17- 19. Among African Americans, 7 (2) SNPs were genome-wide significant in the recessive
(categorical) model specification. SNP rs12082252 was among the significant 7 in the recessive model, and the
2 SNPs significant in the categorical model (rs4612347 and rs1632962) were also significant in the recessive
model and ranked 22467th and 404712th respectively in the CoCoBOT model. No SNPs were genome-wide
significant among Europeans, and only one SNP, rs1511185 (P = 4.08×10−8) was significant among Hispan-
ics under the CoCoBOT model. Based on the rankings from Table 9, there appears to be a similar pattern
of detection between the CoCoBOT and additive model, and between the recessive and categorical model.
Table 20 shows results of analyses of all subjects using baseline bilirubin as outcome. As expected, several
polymorphisms in the UGT1A1 gene were associated with baseline plasma bilirubin; 8, 16, 8 and 9 SNPs
were genome-wide significant under the CoCoBOT, additive, recessive and categorical model specifications
respectively. Surprisingly, no polymorphisms were detected by the dominant model.
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Table 9 TDF clearance: Rank of SNPs with the smallest p-values in combined group analysis
CoCoBOT Additive Dominant Recessive Categorical
SNP rank P rank P rank P rank P rank P
rs12387850 1 2.80e-07 1 1.26e-06 1 5.63e-07 75 1.07e-05 26 3.71e-06
rs1141034 2 2.63e-06 41 4.28e-05 6 8.05e-06 135848 1.59e-01 118 4.74e-05
rs4688755 3 4.28e-06 20 2.74e-05 67 8.39e-05 4543 3.70e-03 213 1.14e-04
rs6653311 4 4.88e-06 18 2.57e-05 50 5.67e-05 146 3.70e-05 257 1.41e-04
rs2883057 5 4.92e-06 25 2.99e-05 68 8.48e-05 4727 3.88e-03 230 1.23e-04
rs4688690 6 4.92e-06 26 2.99e-05 69 8.48e-05 4728 3.88e-03 231 1.23e-04
rs2526751 7 4.92e-06 27 2.99e-05 70 8.48e-05 4729 3.88e-03 232 1.23e-04
rs9311446 8 4.92e-06 28 2.99e-05 71 8.48e-05 4730 3.88e-03 233 1.23e-04
rs12420080 9 4.92e-06 57 5.03e-05 15 2.14e-05 716294 8.56e-01 197 1.01e-04
rs4688758 10 5.04e-06 24 2.95e-05 74 8.60e-05 4678 3.82e-03 229 1.22e-04
GA032783 23 1.68e-05 2 2.14e-06 97 1.09e-04 19 1.98e-06 4 8.75e-08
rs4891230 4024 4.53e-03 3 6.46e-06 870 9.85e-04 30 2.98e-06 19 2.30e-06
rs9950415 642 6.62e-04 4 6.76e-06 28 3.53e-05 5360 4.57e-03 107 3.98e-05
rs2478851 54 4.92e-05 5 9.58e-06 44 4.67e-05 3135 2.35e-03 127 5.41e-05
rs11165778 76 7.63e-05 6 9.59e-06 64 8.15e-05 3030 2.26e-03 110 4.22e-05
rs8001616 7408 8.60e-03 7 9.66e-06 178 1.93e-04 512 2.47e-04 45 1.42e-05
rs11723812 414 4.15e-04 8 1.19e-05 5 7.41e-06 87153 9.97e-02 105 3.87e-05
rs1375178 32 3.03e-05 9 1.27e-05 144 1.58e-04 3572 2.76e-03 148 7.03e-05
rs199529 27 2.58e-05 10 1.41e-05 18 2.84e-05 9636 9.11e-03 144 6.89e-05
rs12082252 346688 4.14e-01 1924 2.03e-03 90918 1.09e-01 1 2.28e-10 2 1.69e-09
rs337298 546883 6.54e-01 47735 5.58e-02 694376 8.31e-01 2 7.58e-10 1 7.80e-10
rs16823145 23568 2.80e-02 60 5.38e-05 4018 4.90e-03 3 3.01e-08 3 4.87e-08
rs263053 75194 8.89e-02 1293 1.28e-03 101034 1.21e-01 4 4.27e-08 5 3.02e-07
rs854207 73839 8.73e-02 2920 3.13e-03 97215 1.16e-01 5 1.51e-07 12 9.59e-07
rs966634 193015 2.29e-01 3361 3.64e-03 66317 7.95e-02 6 3.28e-07 17 1.61e-06
rs6695258 23840 2.84e-02 90 7.63e-05 4202 5.10e-03 7 3.85e-07 7 5.76e-07
rs9982266 14065 1.65e-02 576 5.28e-04 11433 1.36e-02 8 4.80e-07 13 1.07e-06
rs4391664 775385 9.29e-01 57553 6.75e-02 493459 5.90e-01 9 5.11e-07 21 2.79e-06
rs1469386 24915 2.96e-02 1572 1.63e-03 309053 3.70e-01 10 5.14e-07 23 3.11e-06
rs3815748 19 1.44e-05 11 1.43e-05 2 5.17e-06 339831 4.05e-01 88 3.11e-05
rs6878929 145 1.52e-04 86 7.16e-05 3 6.96e-06 560668 6.70e-01 54 1.60e-05
rs12929434 56 5.03e-05 44 4.44e-05 4 7.09e-06 794567 9.51e-01 79 2.45e-05
rs12440239 586 6.02e-04 1056 1.03e-03 7 1.00e-05 717434 8.58e-01 84 2.68e-05
rs7144413 45 4.18e-05 120 1.03e-04 8 1.14e-05 70748 8.01e-02 136 6.41e-05
rs7687008 292 2.84e-04 216 1.77e-04 9 1.26e-05 116180 1.35e-01 156 7.30e-05
rs1230103 48 4.53e-05 32 3.42e-05 10 1.65e-05 40370 4.42e-02 160 7.46e-05
rs7849259 416339 4.97e-01 389042 4.63e-01 375670 4.50e-01 14 6.83e-07 6 4.91e-07
rs12479145 133326 1.58e-01 82308 9.67e-02 195501 2.34e-01 46 3.32e-06 8 6.08e-07
rs17641977 29863 3.55e-02 414 3.71e-04 2089 2.45e-03 32 3.02e-06 9 6.69e-07
rs11791293 25726 3.06e-02 52 4.75e-05 784 8.86e-04 45 3.21e-06 10 6.81e-07
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Creatinine clearance association analyses
Table 10 shows a pairwise correlation matrix of p-values from the combined group analyses under the
five different analysis models. A similar pattern of correlation as that seen in the tenofovir pharmacokinetic
analyses is observed here. In the combined group analyses, CoCoBOT is strongly correlated with the
additive model(ρ = 0.769) and the dominant model (ρ = 0.684), but weakly correlated with the recessive
model (ρ = 0.195). Similar results were observed for the stratified analysis by race/ethnicity (not shown).
Table 21 in Appendices shows the correlation matrix of p-values from analysis with baseline plasma bilirubin
as outcome, which show a similar pattern to that seen in Table 10.
Table 10 6-month CrCl change: Correlation matrix of p-values from combined group analysis
CoCoBOT Additive Dominant Recessive Categorical
CoCoBOT 1
Additive 0.769 1
Dominant 0.684 0.736 1
Recessive 0.195 0.318 0.065 1
Categorical 0.542 0.647 0.648 0.646 1
The 10 SNPs with the smallest p-values in the analyses of all subjects regardless of race are shown in
Table 11. Of all five models, only the recessive model showed genome-wide association with three poly-
morphisms (rs10841159, P = 1.82 × 10−8; rs7297759, P = 1.82 × 10−8; and rs2926112, P = 4.86 × 10−8).
Although not significant, these three SNPs were also the top three SNPs in the categorical model.
Table 11 6-month CrCl change: SNPs with the smallest p-values in combined group analysis
CoCoBOT Additive Dominant Recessive Categorical
CHR SNP P CHR SNP P CHR SNP P CHR SNP P CHR SNP P
3 rs9820757 2.62e-06 15 rs7173993 2.28e-06 3 rs9820757 1.71e-07 12 rs10841159 1.82e-08 8 rs2926112 6.97e-08
15 rs12594783 4.67e-06 15 rs17703807 5.64e-06 1 rs1336625 9.13e-07 12 rs7297759 1.82e-08 12 rs7297759 7.74e-08
9 rs10820825 8.91e-06 15 rs12594783 5.77e-06 1 rs549319 2.76e-06 8 rs2926112 4.86e-08 12 rs10841159 9.06e-08
15 rs8033975 9.59e-06 7 rs2191496 8.32e-06 20 rs6031252 3.35e-06 13 rs7338174 1.13e-07 8 rs7003737 2.56e-07
8 rs16892482 1.03e-05 19 rs2168632 9.39e-06 3 rs9860804 4.51e-06 12 rs4274241 1.43e-07 13 rs7338174 4.86e-07
7 rs10253780 1.49e-05 6 rs6557351 1.17e-05 3 rs1112792 4.69e-06 8 rs7003737 1.89e-07 12 rs4274241 5.21e-07
7 rs2191496 1.53e-05 1 rs645945 1.26e-05 15 rs8033975 5.04e-06 11 rs2230274 2.27e-07 8 rs16902124 5.45e-07
3 rs7650374 1.64e-05 3 rs10490834 1.30e-05 17 rs8078518 8.43e-06 6 rs12333018 3.03e-07 3 rs9820757 6.25e-07
15 rs7181586 1.97e-05 1 rs1931077 1.30e-05 7 rs2191496 1.02e-05 19 rs4474816 6.81e-07 8 rs2960488 8.66e-07
1 rs1931077 2.10e-05 6 rs2185112 1.33e-05 3 rs6550032 1.40e-05 19 rs4807371 6.81e-07 11 rs2230274 1.13e-06
Table 12 shows the ranks of the unique SNPs from Table 11 under each analysis model, and their
respective p-values. SNP rs10841159 ranked 25828th in the CoCoBOT, 41st in the additive; 12105th in the
dominant and 3rd in the categorical models. On the other hand, rs7297759 ranked 26854th in the CoCoBOT,
30th in the additive, 9597th in the dominant and 2nd in the categorical models.
Tables 22- 24 of Appendix C show results of similar analyses (top 10 SNPs), stratified by PC-inferred
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Table 12 6-month CrCl change: Rank of SNPs with the smallest p-values in combined group analysis
CoCoBOT Additive Dominant Recessive Categorical
SNP rank P rank P rank P rank P rank P
rs9820757 1 2.62e-06 36 4.77e-05 1 1.71e-07 640163 7.60e-01 8 6.25e-07
rs12594783 2 4.67e-06 3 5.77e-06 1374 1.57e-03 35 6.55e-06 24 6.75e-06
rs10820825 3 8.91e-06 12 1.57e-05 12 1.76e-05 79939 9.35e-02 121 7.78e-05
rs8033975 4 9.59e-06 53 6.50e-05 7 5.04e-06 85598 1.00e-01 57 2.99e-05
rs16892482 5 1.03e-05 52 6.45e-05 71 9.94e-05 66557 7.74e-02 402 3.39e-04
rs10253780 6 1.49e-05 28 3.93e-05 33 4.78e-05 42022 4.83e-02 212 1.65e-04
rs2191496 7 1.53e-05 4 8.32e-06 9 1.02e-05 28286 3.19e-02 68 3.94e-05
rs7650374 8 1.64e-05 11 1.51e-05 7457 8.70e-03 74 2.27e-05 67 3.90e-05
rs7181586 9 1.97e-05 50 6.40e-05 17 2.67e-05 227252 2.70e-01 190 1.48e-04
rs1931077 10 2.10e-05 9 1.30e-05 32 4.74e-05 2786 2.59e-03 92 5.87e-05
rs7173993 928 1.16e-03 1 2.28e-06 60 8.49e-05 113 4.15e-05 12 2.15e-06
rs17703807 208 2.56e-04 2 5.64e-06 67 9.25e-05 881 6.67e-04 55 2.77e-05
rs2168632 45 6.29e-05 5 9.39e-06 308 3.74e-04 358 2.17e-04 78 4.63e-05
rs6557351 35 4.85e-05 6 1.17e-05 958 1.10e-03 217 1.12e-04 65 3.88e-05
rs645945 53 7.30e-05 7 1.26e-05 164 2.08e-04 1891 1.64e-03 107 6.87e-05
rs10490834 11 2.31e-05 8 1.30e-05 16 2.48e-05 31172 3.53e-02 113 7.31e-05
rs2185112 41 5.95e-05 10 1.33e-05 1834 2.13e-03 114 4.15e-05 56 2.90e-05
rs10841159 25828 3.18e-02 41 5.53e-05 12105 1.40e-02 1 1.82e-08 3 9.06e-08
rs7297759 26854 3.30e-02 30 4.15e-05 9597 1.11e-02 2 1.82e-08 2 7.74e-08
rs2926112 832804 9.88e-01 200227 2.37e-01 581685 6.87e-01 3 4.86e-08 1 6.97e-08
rs7338174 157916 1.91e-01 20472 2.39e-02 99258 1.17e-01 4 1.13e-07 5 4.86e-07
rs4274241 28400 3.49e-02 49 6.31e-05 9042 1.05e-02 5 1.43e-07 6 5.21e-07
rs7003737 823043 9.76e-01 225009 2.66e-01 518513 6.13e-01 6 1.89e-07 4 2.56e-07
rs2230274 158597 1.92e-01 78754 9.29e-02 203969 2.40e-01 7 2.27e-07 10 1.13e-06
rs12333018 666887 7.92e-01 122506 1.44e-01 818529 9.70e-01 8 3.03e-07 11 1.18e-06
rs4474816 238439 2.87e-01 18705 2.18e-02 159513 1.87e-01 9 6.81e-07 18 4.18e-06
rs4807371 189103 2.28e-01 12143 1.40e-02 119001 1.40e-01 10 6.81e-07 17 3.96e-06
rs1336625 1143 1.42e-03 367 4.24e-04 2 9.13e-07 493673 5.87e-01 13 2.68e-06
rs549319 691 8.83e-04 400 4.61e-04 3 2.76e-06 345209 4.10e-01 37 1.16e-05
rs6031252 349 4.51e-04 211 2.66e-04 4 3.35e-06 606421 7.20e-01 40 1.36e-05
rs9860804 18 3.28e-05 321 3.77e-04 5 4.51e-06 602277 7.15e-01 47 1.78e-05
rs1112792 12 2.58e-05 665 7.41e-04 6 4.69e-06 608413 7.22e-01 25 6.83e-06
rs8078518 198 2.34e-04 54 6.52e-05 8 8.43e-06 51651 5.96e-02 80 4.70e-05
rs6550032 37 5.05e-05 410 4.72e-04 10 1.40e-05 592278 7.03e-01 88 5.54e-05
rs16902124 211388 2.55e-01 822965 9.76e-01 110320 1.30e-01 30 5.15e-06 7 5.45e-07
rs2960488 724363 8.60e-01 266864 3.15e-01 494636 5.84e-01 11 7.46e-07 9 8.66e-07
race/ethnicity. Only 2 SNPs (rs9959038, P = 1.50 × 10−8 and rs4934394, P = 2.80 × 10−8) under the
recessive model specification were genome-wide significant among African Americans; these two SNPs were
also among the top 3 in the categorical model, but were ranked much lower in CoCoBOT, additive and
dominant models. 6 (5) SNPs were associated with 6-month CrCl change among Hispanics in the recessive
(categorical) models, with a notable overlap in the top SNPs between the two models. No polymorphisms
were genome-wide significant among Europeans.
Results of combined analyses using baseline bilirubin as outcome are shown in Appendix C, Table 25.
Confirming that our analyses could detect true associations, multiple SNPs in UGT1A1 were associated with
baseline bilirubin; 35, 45, 18, 15 and 28 SNPs were associated with baseline bilirubin under the CoCoBOT,
additive, dominant, recessive and categorical models respectively.
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Discussion
In this case study, we compared the SNP detection performance of a new method (CoCoBOT) and
that of the commonly used model specifications for genetic data analysis (additive, recessive, dominant,
categorical). The association between genotype and two phenotypes (tenofovir clearance and 6-month CrCl
change), after adjusting for other covariates, was evaluated in a diverse group of HIV-infected subjects
randomized to tenofovir-containing regimens in a prospective clinical trial.
For all combined group and stratified analyses, the pairwise correlation matrices showed strong (weak)
correlation between the p-values from the CoCoBOT and additive (recessive) models. Correlations of about
the same magnitude were also seen between the categorical and additive, recessive and dominant models.
Although we observed this pattern of correlation, it did not always correspond to the ranks and p-values of
the SNPs detected by each of the five models. For instance, in the combined group analysis with tenofovir
clearance as the outcome (Table 8), the top SNP (rs12387850) in the CoCoBOT model was the same
SNP in the additive and dominant models, but this similarity in ranking was not observed for the other
SNPs. However, across most analyses, we saw a very similar pattern of detection between the recessive
and categorical model specifications in that both models often detected the same top SNPs. Moreover,
these two models tended to detect positive associations between SNPs and the two phenotypes in most
of the analyses. For instance, in the tenofovir pharmacokinetic analyses, only these two models identified
associations in the combined and African American groups. In the CrCl association analyses, only the
recessive model detected positive associations in the combined and African American group analyses, and
both the categorical and recessive models detected associations among Hispanics. These results suggest a
similarity in the detection behavior of the recessive and categorical models, which could be explained partly
by the possibility that most of the effect is driven by one genotype category (a/a in this case since the
recessive model requires this genotype to show an effect).
No polymorphisms were significant in the CrCl association analyses under the CoCoBOT model spec-
ification. However, in the TDF pharmacokinetic analyses, CoCoBOT detected a positive association with
rs1511185 in the CTNNA2 gene (chromosome 2) among Hispanics. Although this is not one of the SNPs
known to be linked to tenofovir-related phenotypes, it showed the ability to detect positive associations with
CoCoBOT. In addition, there was some overlap in the top SNPs identified by the CoCoBOT and additive
models, especially with the known UGT1A1 polymorphisms in the baseline bilirubin analyses (Tables 20
and 25).
Among the SNPs that were positively associated with tenofovir clearance in the combined group
analyses under the recessive model, rs12082252 is located in the TIPRL gene, rs337298 is located in the
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WDR47 gene and rs16823145 is located in the C1orf21 gene. None of these genes have been linked to
tenofovir-related phenotypes, and their significance to this study is not clear. Of all the top SNPs shown in
Table 8 and 11, none were SNPs that have been identified to be associated with tenofovir pharmacokinetics
and kidney-related phenotypes respectively.
Although the combined group analyses had over 500 subjects, the stratified analyses per race/ethnicity
group had few individuals, possibly resulting in low power to detect SNPs across the five analysis models.
Another limitation of this study specific to CoCoBOT is that presently, it cannot handle testing for
interaction effects between genotype and other covariates as may be desired in some situations. As a result,
we could not for instance, test for interactions with genotype and treatment arm (TDF or abacavir) as was
done in Chapter II with the additive model. Thus, extension of CoCoBOT to handle interactions with the
ordinal predictor is future work.
In summary, we identified some significant associations with TDF clearance and CrCl, especially using
the recessive and categorical models. However, since most of the polymorphisms were not any of the ones
that have been reported in previous studies to be associated with tenofovir or CrCl-related phenotypes,
it is unclear if they are new hits, or whether the identified effects were driven by some unknown factor.
Candidate gene studies could shed more light into these findings, and further research in different study
populations receiving other tenofovir-containing regimens is necessary.
Finally, CoCoBOT was seen to have the ability to detect SNPs, just like the other model specifications,
especially with known UGT1A1 SNPs and baseline plasma bilirubin concentration. Thus, CoCoBOT
could be an option to consider in genetic data analyses because of the fewer model assumptions it
makes when a predictor is ordinal. However, based on the simulation results, using CoCoBOT did
not seem to result in much gain in power to detect genetic associations; except under the truth, the
additive and categorical models seemed to perform more robustly in most data generation scenarios,
including the non-linear settings. Evaluating the performance of CoCoBOT in candidate gene studies
and in cases where genotype is interacted with other covariates may yield different results, but based on
the findings from this study, the additive or categorical models are adequately powerful to detect associations.
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CHAPTER V
Conclusions
In this project, we introduced a new method (CoCoBOT) to detect SNPs in a genome-wide association
study. Using simulations, we evaluated and discussed the statistical performance of CoCoBOT and compared
this to the performance of additive, dominant, recessive and categorical models in a setting where the out-
come is continuous and the main predictor, genotype, is ordered categorical. The motivation was that unlike
the other models, CoCoBOT allows a monotone relationship between the outcome and the ordinal predictor.
The comparison of the power of these methods to detect genetic associations indicated that CoCoBOT does
not appear to be the best choice for genetic association studies. Like the other models, CoCoBOT had
high power under higher minor allele frequencies (MAFs) and struggled under low MAFs, especially when
the data are generated under the recessive model. This is believed to be due to the fact that at such low
frequencies, the genotype effect is mainly due to the minor allele, a and the probability of observing the a/a
genotype category is very low. In addition, the low power under the recessive model is believed to be due
to the fact that the main effect is driven by only one category (a/a), and the probability of observing this
category is very low.
Although in some instances CoCoBOT performed better than the additive model, their power to detect
associations did not differ by large magnitudes, resulting in no unequivocal winner between the two models
in settings other than the truth. Except under the properly specified models, the categorical model did not
lag behind in comparison to the CoCoBOT and additive models; for instance, at MAF = 0.5 under the
dominant and recessive data generation models, the categorical model outperformed both CoCoBOT and
the additive model. Furthermore, at MAFs of 0.3 and 0.1, the categorical model was not the worst of the
other of the models that were not the truth. This indicates that in situations where the data generation
model is unknown, the categorical model may be a robust choice.
Based on the case study using ACTG Protocol A5202 data, CoCoBOT had the ability to detect SNPs.
Although the recessive and categorical models detected most positive associations, none of them were known
associations with tenofovir clearance or changes in creatinine clearance. This leaves a new area for future
investigations. Candidate SNPs/genes analyses may reveal more about the detection performance of Co-
CoBOT and the other four models with polymorphisms that have been reported in literature to be associated
with tenofovir clearance and kidney-related phenotypes.
A strength of the analyses we performed was that it involved individuals from a diverse population, and
the combined analyses allowed the evaluation of over 500 samples. However, it is possible that small sample
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sizes may have contributed to low detection power in the stratified analyses by race/ethnicity. Therefore,
stratified analyses with larger samples could yield higher detection power.
In Chapter II, where we conducted analyses using an additive model with 6-month CrCl change as the
outcome, we were able to include the interaction of genotype and treatment group (tenofovir or abacavir).
However, in the case study in Chapter IV, we were unable to test for this interaction as desired due to
CoCoBOT’s present inability to handle interactions. Therefore, improvements of the method to allow inter-
actions with ordinal predictors need to be made to allow the evaluation of a wide array of research questions.
In conclusion, based on the simulations carried out, the additive, categorical and CoCoBOT models, in
that order, would be recommended for analysis of genetic associations. This is because it the model that real
data follow is typically not known, and when recessive model is true, the dominant model performs worse
than the other models and when the dominant model is true, the recessive models performs worse than the
other models. However, it is important to note that not much detection power is gained in using CoCoBOT
when compared to the additive or categorical models in most of the settings we evaluated This is seen both
in the results from the simulations and case study with real data. Thus, CoCoBOT can be suitable for
exploratory purposes on detection performance of SNPs; beyond that the currently avaialble methods are
robust when chosen appropriately.
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Appendices
A Tenofovir pharmacokinetic (PK) and creatinine clearance asso-
ciation results from Chapter II
Table 13 shows the 20 SNPs with lowest p-values in each analysis with tenofovir clearance as the outcome.
Table 14 shows the 20 SNPs with lowest p-values in each analysis with time-dependent CrCl change as
the outcome.
Table 15 shows the 20 SNPs with lowest p-values in each sensitivity analysis with 6-month CrCl change
as the outcome.
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Table 13 Tenofovir Pharmacokinetic (PK) Association Results (20 SNPs with lowest p-values in each
analysis)
Combined Group African Americans Europeans Hispanics
SNP CHR P SNP CHR P SNP CHR P SNP CHR P
Genome-wide SNPs
GA032783 17 2.1e-06 rs7645493 3 2.5e-06 rs6575267 14 2.1e-07 rs9648724 7 1.1e-06
rs4891230 18 6.5e-06 rs8040826 15 3.5e-06 rs7160376 14 2.3e-06 rs2398827 9 3.1e-06
rs9950415 18 6.8e-06 rs2570249 15 4.8e-06 rs4401457 4 5.2e-06 rs4282783 1 6.5e-06
rs2478851 9 9.6e-06 rs2570218 15 4.8e-06 rs10013079 4 5.4e-06 rs10912094 1 9.3e-06
rs11165778 1 9.6e-06 rs2554341 15 6.1e-06 rs1317816 6 5.4e-06 rs1732103 4 1.3e-05
rs8001616 13 9.7e-06 rs2554321 15 6.1e-06 rs4712976 6 7.7e-06 rs1250105 4 1.3e-05
rs11723812 4 1.2e-05 rs4309482 18 8.8e-06 rs718763 2 9.6e-06 rs4357909 15 1.5e-05
rs1375178 2 1.3e-05 rs10823406 10 9.3e-06 rs609949 18 1.3e-05 rs4743894 9 1.7e-05
rs199529 17 1.4e-05 rs4858429 3 9.7e-06 rs7749149 6 1.3e-05 rs10985148 9 1.7e-05
rs3815748 19 1.4e-05 rs11906888 20 1.0e-05 rs567338 18 1.6e-05 rs4710994 6 2.1e-05
rs9854936 3 1.8e-05 rs2200488 2 1.2e-05 rs1408271 6 1.7e-05 rs6137387 20 2.1e-05
rs6999964 8 1.9e-05 rs6133987 20 1.4e-05 rs2720823 8 1.9e-05 rs12718174 7 2.3e-05
rs1548896 2 2.1e-05 rs369427 1 1.9e-05 rs7653963 4 2.0e-05 rs10227315 7 2.3e-05
rs4074408 18 2.2e-05 rs11177175 12 1.9e-05 rs3778272 6 2.0e-05 rs10040797 5 2.6e-05
rs17199679 9 2.4e-05 rs3762872 16 2.1e-05 rs1892248 6 2.0e-05 rs12578725 12 2.7e-05
rs6429178 1 2.5e-05 rs2289430 16 2.1e-05 rs4712970 6 2.0e-05 rs7548935 1 2.8e-05
rs4688755 3 2.7e-05 rs2277968 19 2.3e-05 rs1317510 6 2.0e-05 rs12080794 1 2.9e-05
rs1382101 8 2.8e-05 rs9865933 3 2.7e-05 rs9759759 4 2.0e-05 rs8008246 14 2.9e-05
rs247938 5 2.9e-05 rs126917 20 2.8e-05 rs10031444 4 2.2e-05 rs10993725 9 3.0e-05
rs4688758 3 3.0e-05 rs12211633 6 2.8e-05 rs10000845 4 2.2e-05 rs876670 10 3.1e-05
30 Candidate SNPs
rs456374 9 0.002268 rs465793 9 0.00025 rs1729741 13 0.02182 rs17268122 13 0.000436
rs465793 9 0.003149 rs456374 9 0.00311 rs17268170 13 0.0253 rs17268163 13 0.000580
rs16921966 9 0.006022 rs9561811 13 0.00930 rs17268129 13 0.03852 rs2159359 17 0.000653
rs1189462 13 0.007878 rs2274410 13 0.00999 rs873705 13 0.04253 rs2041296 17 0.000929
rs3847258 9 0.009197 rs6949448 7 0.01043 rs1751027 13 0.04335 rs12864844 13 0.001003
rs9561765 13 0.01058 rs10276036 7 0.01186 rs11231302 11 0.04396 rs17189446 13 0.001342
rs1189461 13 0.01405 rs3818494 13 0.01207 rs2159359 17 0.05364 rs12864049 13 0.001807
rs1751037 13 0.01405 rs12704364 7 0.01235 rs11591185 1 0.06099 rs1479389 13 0.003163
rs7330330 13 0.01616 rs6961665 7 0.01235 rs4773840 13 0.06527 rs8075231 17 0.003591
rs403860 9 0.01635 rs2274408 13 0.01579 rs1611822 13 0.06789 rs17189376 13 0.003705
rs4148540 13 0.02114 rs1202170 7 0.01682 rs1564351 13 0.06885 rs12584534 13 0.00404
rs7331488 13 0.02114 rs17189481 13 0.01761 rs4148487 13 0.06947 rs4771912 13 0.004216
rs1189464 13 0.02581 rs2235046 7 0.01892 rs1678341 13 0.07359 rs4773843 13 0.01593
rs1189466 13 0.0275 rs2235033 7 0.01925 rs6492768 13 0.07713 rs17189299 13 0.01671
rs1678387 13 0.0275 rs1202169 7 0.02112 rs12429339 13 0.09089 rs9524822 13 0.01918
rs1678409 13 0.02843 rs10274587 7 0.02313 rs1678384 13 0.09237 rs1611822 13 0.01979
rs1678365 13 0.02887 rs2235040 7 0.02313 rs10161985 13 0.09639 rs9524849 13 0.02633
rs4148430 13 0.02938 rs7981095 13 0.0232 rs2185631 6 0.09751 rs1048020 9 0.02969
rs1729745 13 0.02955 rs4148747 7 0.02458 rs9349256 6 0.09956 rs1729764 13 0.02996
rs2766475 13 0.02987 rs1202172 7 0.02498 rs9394952 6 0.09956 rs3765535 13 0.02996
594 Candidate SNPs
rs456374 9 0.002268 rs465793 9 0.00025 rs1729741 13 0.02182 rs17268122 13 0.000436
rs465793 9 0.003149 rs456374 9 0.00311 rs17268170 13 0.0253 rs17268163 13 0.000580
rs16921966 9 0.006022 rs9561811 13 0.00930 rs17268129 13 0.03852 rs2159359 17 0.000653
rs1189462 13 0.007878 rs2274410 13 0.00999 rs873705 13 0.04253 rs2041296 17 0.000929
rs3847258 9 0.009197 rs6949448 7 0.01043 rs1751027 13 0.04335 rs12864844 13 0.001003
rs9561765 13 0.01058 rs10276036 7 0.01186 rs11231302 11 0.04396 rs17189446 13 0.001342
rs1189461 13 0.01405 rs3818494 13 0.01207 rs2159359 17 0.05364 rs12864049 13 0.001807
rs1751037 13 0.01405 rs12704364 7 0.01235 rs11591185 1 0.06099 rs1479389 13 0.003163
rs7330330 13 0.01616 rs6961665 7 0.01235 rs4773840 13 0.06527 rs8075231 17 0.003591
rs403860 9 0.01635 rs2274408 13 0.01579 rs1611822 13 0.06789 rs17189376 13 0.003705
rs4148540 13 0.02114 rs1202170 7 0.01682 rs1564351 13 0.06885 rs12584534 13 0.00404
rs7331488 13 0.02114 rs17189481 13 0.01761 rs4148487 13 0.06947 rs4771912 13 0.004216
rs1189464 13 0.02581 rs2235046 7 0.01892 rs1678341 13 0.07359 rs4773843 13 0.01593
rs1189466 13 0.0275 rs2235033 7 0.01925 rs6492768 13 0.07713 rs17189299 13 0.01671
rs1678387 13 0.0275 rs1202169 7 0.02112 rs12429339 13 0.09089 rs9524822 13 0.01918
rs1678409 13 0.02843 rs10274587 7 0.02313 rs1678384 13 0.09237 rs1611822 13 0.01979
rs1678365 13 0.02887 rs2235040 7 0.02313 rs10161985 13 0.09639 rs9524849 13 0.02633
rs4148430 13 0.02938 rs7981095 13 0.0232 rs2185631 6 0.09751 rs1048020 9 0.02969
rs1729745 13 0.02955 rs4148747 7 0.02458 rs9349256 6 0.09956 rs1729764 13 0.02996
rs2766475 13 0.02987 rs1202172 7 0.02498 rs9394952 6 0.09956 rs3765535 13 0.02996
Significance threshold was: 5×10−8 for genome-wide SNPs, 0.002 for the subset of 30 SNPs, 8.4×10−5 for the subset
of 594 SNPs.
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Table 14 Creatinine Clearance Association Results (20 SNPs with lowest p-values in each analysis)
Combined Group African Americans Europeans Hispanics
SNP CHR P SNP CHR P SNP CHR P SNP CHR P
Genome-wide SNPs
rs4435343 18 1.24e-06 rs10827791 10 1.79e-06 rs11114652 12 2.91e-06 rs17062791 8 1.77e-07
rs6533668 4 9.28e-06 rs11106805 12 3.38e-06 rs4962347 10 4.35e-06 rs4936767 11 6.22e-07
rs2352185 4 9.92e-06 rs10786737 10 3.60e-06 rs17804080 12 4.79e-06 rs7109445 11 7.08e-07
rs2011706 21 1.12e-05 rs6863176 5 3.76e-06 rs16918212 12 6.76e-06 rs4936770 11 8.86e-07
rs11082117 18 1.29e-05 rs7996510 13 5.70e-06 rs7585799 2 7.35e-06 rs2226150 6 1.95e-06
rs12953983 18 1.48e-05 rs2571468 4 5.95e-06 rs10399860 1 8.79e-06 rs1592216 6 2.50e-06
rs9323158 14 1.66e-05 rs10827797 10 6.95e-06 rs2129530 11 9.30e-06 rs2883821 1 3.07e-06
rs12597817 16 1.89e-05 rs10521695 23 8.27e-06 rs7903887 10 9.85e-06 rs6677658 1 3.33e-06
rs2407940 8 1.89e-05 rs534613 23 1.41e-05 rs7214860 17 1.09e-05 rs7688805 4 3.73e-06
rs4521822 9 2.00e-05 rs1450657 5 1.51e-05 rs6548164 2 1.17e-05 rs505601 18 4.51e-06
rs656682 10 2.00e-05 rs11953822 5 1.87e-05 rs9576310 13 1.43e-05 rs1935737 6 4.62e-06
rs1364182 16 2.16e-05 rs4242134 5 1.99e-05 rs4514905 2 1.47e-05 rs1342634 6 4.73e-06
rs10853461 18 2.17e-05 rs2249751 6 2.14e-05 rs3812842 13 1.48e-05 rs7064462 23 5.26e-06
rs1886970 13 2.28e-05 rs13711 11 2.21e-05 rs11613504 12 1.88e-05 rs7562658 2 5.65e-06
rs1751036 13 2.41e-05 rs17043253 3 2.26e-05 rs2025405 13 1.88e-05 rs6902991 6 6.09e-06
rs17878498 3 2.41e-05 rs12422149 11 2.31e-05 rs13311400 7 2.09e-05 rs7923837 10 6.71e-06
rs4825731 23 2.43e-05 rs4303 17 2.39e-05 rs1696320 12 2.09e-05 rs4709724 6 6.89e-06
rs11621998 14 2.52e-05 rs10929525 2 2.51e-05 rs2079778 17 2.16e-05 rs7941144 11 7.75e-06
rs4243086 15 2.55e-05 rs8004116 14 2.53e-05 rs1924296 13 2.28e-05 rs12592731 15 7.91e-06
rs1900100 14 2.59e-05 rs11693395 2 2.56e-05 rs10741552 11 2.28e-05 rs36111427 6 8.96e-06
212 Candidate SNPs
rs2082424 19 0.0054 rs3127573 6 0.0018 rs2412971 22 0.0087 rs6036478 20 0.0039
rs7246178 19 0.0058 rs1556751 9 0.0129 rs1260326 2 0.0095 rs6999484 8 0.0086
rs9275596 6 0.0223 rs10941692 5 0.0448 rs2764267 6 0.0311 rs6048952 20 0.0195
rs17272197 19 0.0241 rs923068 18 0.0482 rs1775644 6 0.0360 rs4346460 20 0.0212
rs653178 12 0.0291 rs12520150 5 0.0664 rs948494 11 0.0414 rs7805747 7 0.0224
rs7805747 7 0.0405 rs11871637 17 0.0821 rs12537 22 0.0435 rs2728108 4 0.0231
rs10941692 5 0.0449 rs6465825 7 0.0822 rs16946160 13 0.0469 rs3810575 20 0.0240
rs6677604 1 0.0467 rs1133029 20 0.0835 rs11227281 11 0.0500 rs6677604 1 0.0291
rs12520150 5 0.0478 rs12514615 5 0.0889 rs6420094 5 0.0922 rs10794720 10 0.0417
rs10774021 12 0.0488 rs12522822 5 0.0959 rs9473932 6 0.1021 rs1705699 8 0.0480
rs660895 6 0.0513 rs16902083 5 0.0959 rs2057291 20 0.1035 rs35610040 20 0.0598
rs2239785 22 0.0540 rs4566805 5 0.0959 rs2518322 6 0.1058 rs17751897 20 0.0671
rs9473932 6 0.0687 rs12515820 5 0.1005 rs17272197 19 0.1206 rs3787498 20 0.0725
rs3115573 6 0.0799 rs3813227 2 0.1174 rs2082424 19 0.1216 rs3827142 20 0.0736
rs3127573 6 0.0891 rs10184268 2 0.1178 rs4812042 20 0.1303 rs3787499 20 0.0763
rs1556751 9 0.0924 rs1909937 5 0.1294 rs660895 6 0.1314 rs1719250 15 0.0873
rs1133029 20 0.1085 rs9473932 6 0.1337 rs7246178 19 0.1345 rs3827143 20 0.0906
rs7105665 11 0.1217 rs3115573 6 0.1658 rs6026576 20 0.1355 rs12625716 20 0.0939
rs11871637 17 0.1262 rs1392970 5 0.1865 rs2239785 22 0.1393 rs653178 12 0.0942
rs2277311 11 0.1309 rs6420094 5 0.1889 rs10941692 5 0.1521 rs4664308 2 0.1187
Significance threshold was: 5× 10−8 for genome-wide SNPs, 0.0002 for the subset of 212 SNPs.
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Table 15 Sensitivity Analysis Results for CrCl (20 SNPs with lowest p-values in each analysis)
Combined Group African Americans Europeans Hispanics Meta-analysis
SNP CHR P SNP CHR P SNP CHR P SNP CHR P SNP CHR P
Genome-wide SNPs
rs1397050 11 4.58e-06 rs2480181 6 4.49e-06 rs731580 3 1.03e-06 rs6448638 4 6.79e-07 rs906956 11 4.18e-06
rs121882 5 4.70e-06 rs11106805 12 6.76e-06 rs1733826 7 3.56e-06 rs4435343 18 8.15e-07 rs121882 5 5.62e-06
rs906956 11 6.91e-06 rs12230258 12 9.21e-06 rs2112424 5 3.56e-06 rs1966678 4 1.13e-06 rs11227719 11 5.71e-06
rs13071033 3 7.22e-06 rs309543 1 1.27e-05 rs2438466 5 4.07e-06 rs2226150 6 1.30e-06 GA021270 3 6.30e-06
rs10510580 3 7.22e-06 rs555740 12 1.41e-05 rs16993962 20 7.70e-06 rs16893073 5 1.31e-06 rs1397050 11 6.68e-06
rs4435343 18 1.21e-05 rs11926663 3 2.11e-05 rs2664570 20 8.70e-06 rs13292946 9 1.86e-06 rs17150286 11 8.77e-06
rs193890 7 1.63e-05 rs16864810 2 2.13e-05 rs16994003 20 1.12e-05 rs16867887 4 2.45e-06 rs1842674 11 9.71e-06
rs11227719 11 2.07e-05 rs9373685 6 2.25e-05 rs4809716 20 1.14e-05 rs11103684 9 2.48e-06 GA017257 20 9.97e-06
rs679309 11 2.31e-05 rs4543114 4 2.28e-05 rs729664 20 1.14e-05 rs11834 9 2.48e-06 GA035558 20 1.00e-05
rs12498133 3 2.32e-05 rs1988833 8 2.67e-05 rs11032561 11 1.16e-05 rs2604271 9 2.70e-06 rs16993997 20 1.05e-05
rs193894 7 2.40e-05 rs6862529 5 2.70e-05 rs3757527 7 1.22e-05 rs1592216 6 2.89e-06 rs11227874 11 1.27e-05
rs3117092 1 2.63e-05 rs7088661 10 2.80e-05 rs2294910 20 1.24e-05 rs1935737 6 2.95e-06 rs17286324 3 1.44e-05
rs3117091 1 2.70e-05 rs7651518 3 2.90e-05 rs655754 3 1.86e-05 rs7562658 2 3.08e-06 rs4809719 20 1.49e-05
rs1789041 18 2.72e-05 rs12086858 1 2.93e-05 rs2058298 16 1.89e-05 rs1342634 6 3.59e-06 rs11590226 1 1.61e-05
rs1524930 21 2.85e-05 rs6768930 3 3.07e-05 rs830995 2 2.01e-05 rs625001 18 3.80e-06 rs10896271 11 1.67e-05
rs1842674 11 2.96e-05 rs3127573 6 3.28e-05 rs1003615 16 2.07e-05 rs11103683 9 3.99e-06 rs2833143 21 1.73e-05
rs957215 3 2.96e-05 rs34740624 11 3.43e-05 rs1347382 8 2.08e-05 rs6902991 6 4.00e-06 rs12365860 11 2.09e-05
rs3731711 2 3.03e-05 rs16883776 5 3.50e-05 rs1397050 11 2.42e-05 rs9361224 6 4.69e-06 rs7118155 11 2.24e-05
rs12497411 3 3.09e-05 rs10789496 1 4.03e-05 rs906956 11 2.42e-05 rs904200 16 6.67e-06 rs13071033 3 2.41e-05
rs1862409 5 3.52e-05 rs11713641 3 4.13e-05 rs1812591 16 2.49e-05 rs11981075 7 6.76e-06 rs10510580 3 2.41e-05
212 Candidate SNPs
rs17751897 20 0.00453 rs3127573 c 6 3.28e-05 rs1260326 2 0.01477 rs6036478 20 0.003525 rs10774021 12 0.01532
rs6048952 20 0.00704 rs1556751 9 0.01223 rs10774021 12 0.01952 rs3827142 20 0.003709 rs1260326 2 0.03362
rs2239785 22 0.007497 rs923068 18 0.02742 rs1883414 6 0.03378 rs35610040 20 0.004377 rs11142 1 0.08887
rs12625716 20 0.01177 rs16946160 13 0.03828 rs7422339 2 0.04907 rs13043610 20 0.007981 rs2564002 2 0.0901
rs4346460 20 0.01471 rs17751897 20 0.04128 rs3115573 6 0.04985 rs3787499 20 0.008277 rs17751897 20 0.1003
rs3810575 20 0.01835 rs12625716 20 0.06595 rs2412971 22 0.05236 rs3787498 20 0.008472 rs1158167 20 0.1136
rs1158167 20 0.0272 rs6048952 20 0.07615 rs2239785 22 0.06195 rs3810575 20 0.01057 rs4346460 20 0.1175
rs10774021 12 0.02726 rs9661614 1 0.09001 rs10745354 1 0.0762 rs12523157 5 0.01085 rs12625716 20 0.1222
rs13043610 20 0.03573 rs2564002 2 0.09124 rs4970760 1 0.07879 rs6048952 20 0.0115 rs347685 3 0.1263
rs3127573 6 0.03634 rs3115573 6 0.09299 rs10745352 1 0.08168 rs12515179 5 0.01183 rs4970759 1 0.131
rs6036478 20 0.05022 rs12136063 1 0.097 rs10858085 1 0.08168 rs3827143 20 0.01273 rs6048952 20 0.1465
rs13037490 20 0.07049 rs4928134 3 0.09921 rs10858086 1 0.08168 rs1775644 6 0.01296 rs9310709 3 0.1545
rs1556751 9 0.09159 rs11924318 3 0.1005 rs10858092 1 0.08168 rs17751897 20 0.01312 rs3810575 20 0.1591
rs2722583 2 0.09908 rs12654812 5 0.1033 rs1880670 1 0.08168 rs4346460 20 0.01741 rs7246178 19 0.1764
rs11142 1 0.1046 rs1394125 15 0.1035 rs3768497 1 0.08168 rs12625716 20 0.0229 rs13043610 20 0.1787
rs1260326 2 0.1103 rs12145677 1 0.1036 rs3853501 1 0.08168 rs10794720 10 0.02499 rs12073497 1 0.1797
rs12523157 5 0.1169 rs4849121 2 0.1131 rs3879450 1 0.08168 rs13037490 20 0.02687 rs4970760 1 0.1824
rs2564002 2 0.1304 rs6879012 5 0.1148 rs443345 1 0.08168 rs2239785 22 0.03288 rs10858086 1 0.1831
rs16946160 13 0.1328 rs4849179 2 0.1251 rs444387 1 0.08168 rs12516998 5 0.03385 rs3768497 1 0.1831
rs12073497 1 0.1332 rs1158167 20 0.1271 rs4603158 1 0.08168 rs7711446 5 0.03385 rs1133029 20 0.1839
Significance threshold was: 5 × 10−8 for genome-wide SNPs, 0.0002 for the subset of 212 SNPs. rs3127573 on
chromosome 6 of the SLC22A2 gene was significant in the African American group analysis of candidate SNPs.
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B Chapter IV (Tenofovir pharmacokinetic association analyses)
Table 16 shows the pairwise correlation matrix of p-values from analysis of all subjects with baseline
bilirubin as outcome
Table 16 Baseline bilirubin: Correlation matrix of p-values from combined group analysis
CoCoBOT Additive Dominant Recessive Categorical
CoCoBOT 1
Additive 0.818 1
Dominant 0.724 0.738 1
Recessive 0.206 0.323 0.069 1
Categorical 0.569 0.65 0.65 0.647 1
Tables 17- 19 show the top 10 SNPs with the smallest p-values within each race/ethnicity group under
each of the five analysis models with tenofovir clearance as outcome
Table 17 TDF clearance: SNPs with the smallest p-values among African Americans
CoCoBOT Additive Dominant Recessive Categorical
CHR SNP P CHR SNP P CHR SNP P CHR SNP P CHR SNP P
2 rs3850354 6.64e-07 3 rs7645493 2.50e-06 8 rs2382993 2.98e-06 1 rs12082252 3.08e-08 8 rs4612347 3.42e-08
15 rs8040826 1.59e-06 15 rs8040826 3.48e-06 3 rs6781193 6.37e-06 9 rs4554572 3.08e-08 6 rs1632962 4.98e-08
17 rs17627030 1.65e-06 15 rs2570249 4.78e-06 2 rs266216 6.65e-06 6 rs1632962 3.21e-08 6 rs1632964 6.82e-08
11 rs3108805 2.76e-06 15 rs2570218 4.78e-06 2 rs6531176 6.79e-06 8 rs4612347 3.21e-08 1 rs12082252 1.97e-07
9 rs2382407 3.22e-06 15 rs2554341 6.13e-06 15 rs2570249 7.67e-06 6 rs1632964 3.59e-08 1 rs337298 2.02e-07
3 rs13325221 4.68e-06 15 rs2554321 6.13e-06 15 rs2570218 7.67e-06 8 rs3802143 5.91e-08 9 rs4554572 2.12e-07
11 rs2702676 5.33e-06 18 rs4309482 8.76e-06 15 rs8040826 8.13e-06 8 rs3898300 5.91e-08 8 rs3802143 2.29e-07
1 rs6588444 6.06e-06 10 rs10823406 9.32e-06 11 rs3108805 1.12e-05 1 rs337298 9.50e-08 8 rs3898300 2.29e-07
9 rs1408314 7.59e-06 20 rs11906888 1.01e-05 15 rs2554341 1.15e-05 10 rs11598684 4.75e-07 20 rs1543474 5.09e-07
14 rs7159296 1.01e-05 2 rs2200488 1.22e-05 15 rs2554321 1.15e-05 1 rs369427 5.70e-07 12 rs2250499 2.01e-06
Table 18 TDF clearance: SNPs with the smallest p-values among Europeans
CoCoBOT Additive Dominant Recessive Categorical
CHR SNP P CHR SNP P CHR SNP P CHR SNP P CHR SNP P
14 rs6575267 8.09e-08 14 rs6575267 2.09e-07 14 rs7160376 4.71e-07 2 rs768811 6.64e-07 14 rs6575267 1.29e-06
14 rs7160376 1.99e-07 14 rs7160376 2.30e-06 14 rs6575267 1.11e-06 2 rs1053895 1.05e-06 14 rs7160376 2.62e-06
18 rs609949 1.41e-06 4 rs4401457 5.17e-06 6 rs1317816 1.72e-06 1 rs17125608 1.34e-06 2 rs768811 2.70e-06
10 rs7096455 1.46e-06 4 rs10013079 5.39e-06 6 rs4712976 3.93e-06 2 rs7422272 1.55e-06 2 rs1053895 3.97e-06
10 rs4750961 2.73e-06 6 rs1317816 5.41e-06 6 rs7749149 5.65e-06 5 rs7731904 1.55e-06 1 rs17125608 8.66e-06
6 rs1317816 3.68e-06 6 rs4712976 7.69e-06 6 rs3778272 6.75e-06 21 rs17766637 1.88e-06 2 rs7422272 8.94e-06
2 rs718763 4.51e-06 2 rs718763 9.55e-06 6 rs1892248 6.75e-06 2 rs838731 2.85e-06 1 rs7530493 9.52e-06
6 rs4712976 5.14e-06 18 rs609949 1.27e-05 6 rs4712970 6.75e-06 2 rs838732 2.96e-06 4 rs10020303 9.66e-06
17 rs9914092 6.07e-06 6 rs7749149 1.32e-05 6 rs1317510 6.75e-06 2 rs838715 3.47e-06 6 rs1317816 9.75e-06
6 rs7749149 6.28e-06 18 rs567338 1.55e-05 6 rs1141034 8.25e-06 1 rs1415105 3.70e-06 5 rs7731904 9.88e-06
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Table 19 TDF clearance: SNPs with the smallest p-values among Hispanics
CoCoBOT Additive Dominant Recessive Categorical
CHR SNP P CHR SNP P CHR SNP P CHR SNP P CHR SNP P
2 rs1511185 4.08e-08 7 rs9648724 1.09e-06 9 rs2398827 3.40e-06 11 rs11037953 6.38e-06 7 rs9648724 7.32e-06
9 rs2398827 7.49e-08 9 rs2398827 3.07e-06 7 rs9648724 3.77e-06 7 rs12718174 1.54e-05 20 rs12626158 1.02e-05
9 rs4743894 3.20e-07 1 rs10912094 9.32e-06 8 rs2114018 5.89e-06 7 rs10227315 1.54e-05 9 rs2398827 1.20e-05
7 rs9648724 4.12e-07 4 rs1732103 1.30e-05 8 rs16930786 5.89e-06 5 rs10454913 1.72e-05 22 rs8135417 1.31e-05
1 rs6677872 5.55e-07 4 rs1250105 1.32e-05 8 rs6531002 6.19e-06 7 rs2116020 2.02e-05 6 rs9386463 1.78e-05
14 rs8008246 5.65e-07 15 rs4357909 1.45e-05 20 rs12626158 6.22e-06 15 rs11259921 2.47e-05 7 rs12718174 1.86e-05
6 rs510667 7.50e-07 9 rs4743894 1.70e-05 8 rs7828391 6.36e-06 15 rs4357909 2.52e-05 7 rs10227315 1.86e-05
12 rs7957621 1.62e-06 9 rs10985148 1.71e-05 10 rs876670 6.61e-06 14 rs9323989 2.52e-05 22 rs5997893 1.92e-05
1 rs12080794 1.76e-06 6 rs4710994 2.06e-05 20 rs6137387 7.11e-06 14 rs7148578 2.52e-05 1 rs7523927 3.04e-05
6 rs4710994 1.81e-06 20 rs6137387 2.10e-05 14 rs8008246 7.23e-06 15 rs11633383 2.58e-05 1 rs7517729 3.04e-05
Table 20 shows the top 20 SNPs with the smallest p-values in the analysis of all subjects under each of
the five analysis models with baseline plasma bilirubin as outcome
Table 20 Baseline bilirubin: SNPs with the smallest p-values in combined group analysis
CoCoBOT Additive Dominant Recessive Categorical
CHR SNP P CHR SNP P CHR SNP P CHR SNP P CHR SNP P
2 rs887829 7.08e-10 2 rs887829 2.24e-11 2 rs3755319 1.03e-07 2 rs887829 4.49e-12 2 rs887829 1.74e-12
2 rs4148325 2.54e-09 2 rs4148325 7.30e-11 19 rs4239638 3.74e-07 2 rs4148325 8.81e-12 2 rs4148325 4.60e-12
2 rs6742078 4.87e-09 2 rs6742078 1.32e-10 19 rs7257832 4.52e-07 2 rs6742078 5.13e-11 2 rs6742078 1.69e-11
2 rs4148324 1.04e-08 2 rs4148324 3.11e-10 2 rs4663333 4.68e-07 2 rs929596 1.02e-10 2 rs929596 2.48e-11
2 rs10179091 1.63e-08 2 rs929596 3.39e-10 2 rs4663967 5.17e-07 2 rs4148324 1.05e-10 2 rs4148324 4.39e-11
2 rs3771341 3.07e-08 2 rs3771341 3.89e-10 2 rs4399719 8.00e-07 2 rs3771341 3.36e-10 2 rs3771341 6.07e-11
2 rs929596 3.63e-08 2 rs10179091 3.15e-09 2 rs4124874 1.03e-06 2 rs17862875 6.46e-09 2 rs17862875 2.92e-09
2 rs3755319 4.34e-08 2 rs17862875 1.56e-08 2 rs4663965 1.48e-06 2 rs10179091 2.48e-08 2 rs10179091 1.01e-08
2 rs4148326 6.53e-08 2 rs2221198 2.04e-08 2 rs6431628 2.17e-06 2 rs4148326 6.00e-08 2 rs4148326 5.80e-08
2 rs2221198 1.34e-07 2 rs4663969 2.24e-08 11 rs1560994 2.50e-06 2 rs2221198 1.86e-07 2 rs2221198 6.47e-08
2 rs4663969 1.93e-07 2 rs3755319 2.38e-08 2 rs17862866 2.77e-06 2 rs4663969 2.68e-07 2 rs3755319 7.48e-08
2 rs4663967 2.43e-07 2 rs4148326 2.73e-08 2 rs3806597 2.96e-06 2 rs16862202 2.69e-07 2 rs7604115 7.53e-08
2 rs4663333 2.81e-07 2 rs7604115 2.94e-08 2 rs2008595 3.90e-06 2 rs7556676 4.01e-07 2 rs4663969 7.94e-08
2 rs7556676 2.84e-07 2 rs7556676 3.05e-08 2 rs4294999 3.91e-06 2 rs7604115 4.46e-07 2 rs7556676 1.15e-07
2 rs871514 4.07e-07 2 rs871514 4.00e-08 10 rs7915217 4.02e-06 19 rs8111761 2.67e-06 2 rs4663967 2.53e-07
2 rs4294999 4.80e-07 2 rs4663967 5.55e-08 2 rs871514 4.12e-06 7 rs1395381 2.80e-06 2 rs4663333 2.58e-07
2 rs4663965 5.48e-07 2 rs4663333 5.97e-08 2 rs4663963 4.63e-06 3 rs9310867 4.57e-06 2 rs871514 2.87e-07
2 rs4399719 5.65e-07 2 rs4294999 6.26e-08 19 rs8108083 4.68e-06 12 rs7303705 4.87e-06 14 rs2353726 3.55e-07
2 rs3806597 6.46e-07 2 rs4663965 1.16e-07 6 rs199634 5.13e-06 4 rs3866838 5.14e-06 2 rs4294999 4.28e-07
2 rs7604115 6.46e-07 2 rs4663963 1.33e-07 19 rs2377572 5.64e-06 9 rs7847905 5.53e-06 2 rs4663965 5.99e-07
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C Chapter IV (Creatinine Clearance association analyses)
Table 21 shows the pairwise correlation matrix of p-values from analysis of all subjects with baseline
bilirubin as outcome
Table 21 Baseline bilirubin: Correlation matrix of p-values from combined group analysis
CoCoBOT Additive Dominant Recessive Categorical
CoCoBOT 1
Additive 0.813 1
Dominant 0.72 0.736 1
Recessive 0.204 0.319 0.066 1
Categorical 0.568 0.647 0.65 0.646 1
Tables 22- 24 show the top 10 SNPs with the smallest p-values within each race/ethnicity group under
each of the five analysis models with creatinine clearance as outcome
Table 22 6-month CrCl change: SNPs with the smallest p-values among African Americans
CoCoBOT Additive Dominant Recessive Categorical
CHR SNP P CHR SNP P CHR SNP P CHR SNP P CHR SNP P
4 rs10518639 1.55e-06 13 rs4942321 1.00e-06 17 rs7224983 2.81e-07 18 rs9959038 1.50e-08 18 rs9959038 8.06e-08
23 rs6627929 6.21e-06 17 rs7224983 1.19e-06 16 rs10459845 3.88e-06 10 rs4934394 2.80e-08 13 rs7338174 1.08e-07
17 rs7224983 6.87e-06 12 rs2612060 3.05e-06 2 rs6435051 4.35e-06 13 rs7338174 7.35e-08 10 rs4934394 1.15e-07
15 rs12594783 6.98e-06 1 rs12070814 8.62e-06 7 rs9986688 4.94e-06 5 rs4957646 1.01e-07 18 rs629178 1.52e-07
1 rs12070814 7.35e-06 15 rs12594783 9.19e-06 8 rs6994092 6.21e-06 18 rs629178 1.06e-07 18 rs1443333 2.94e-07
9 rs2298181 8.18e-06 13 rs1327620 1.11e-05 3 rs6799661 8.51e-06 18 rs1443333 1.10e-07 7 rs6973776 3.52e-07
3 rs6792668 8.21e-06 16 rs10459845 1.40e-05 9 rs10812910 9.02e-06 14 rs2415485 1.31e-07 5 rs11960184 4.58e-07
2 rs17045635 8.36e-06 7 rs9986688 1.64e-05 9 rs10812913 1.02e-05 18 rs997105 1.63e-07 16 rs8063242 5.50e-07
10 rs2839658 8.85e-06 3 rs900370 1.66e-05 11 rs2291841 1.09e-05 6 rs3749930 2.52e-07 11 rs7950161 5.58e-07
7 rs9986688 9.45e-06 17 rs9908413 1.79e-05 13 rs1327620 1.40e-05 8 rs7003737 2.61e-07 11 rs7937105 5.58e-07
Table 23 6-month CrCl change: SNPs with the smallest p-values among Europeans
CoCoBOT Additive Dominant Recessive Categorical
CHR SNP P CHR SNP P CHR SNP P CHR SNP P CHR SNP P
3 rs9820757 1.14e-06 5 rs1825192 7.27e-07 2 rs11682044 6.98e-07 4 rs16856919 5.02e-06 5 rs1825192 3.82e-06
6 rs977608 1.25e-06 3 rs7642361 2.73e-06 2 rs13388291 1.58e-06 4 rs4419508 5.02e-06 2 rs11682044 4.53e-06
10 rs10901541 1.77e-06 3 rs1604380 3.02e-06 2 rs13432998 1.65e-06 9 rs2905476 9.65e-06 3 rs7642361 5.75e-06
3 rs6808005 2.32e-06 8 rs4377920 3.52e-06 2 rs6545026 2.28e-06 8 rs7814638 1.11e-05 6 rs9388813 6.83e-06
3 rs2201439 2.45e-06 8 rs7003418 3.64e-06 6 rs977608 4.86e-06 8 rs6987706 1.15e-05 3 rs1604380 8.49e-06
8 rs4377920 2.64e-06 2 rs6545026 3.83e-06 2 rs11676168 4.90e-06 2 rs2723190 1.27e-05 2 rs13388291 8.62e-06
3 rs6550032 2.66e-06 8 rs10216910 4.26e-06 8 rs4732890 5.64e-06 2 rs2723168 1.28e-05 2 rs13432998 9.45e-06
8 rs7003418 3.52e-06 8 rs4732832 4.66e-06 8 rs4732657 5.64e-06 2 rs2708964 1.33e-05 2 rs6545026 9.89e-06
8 rs4732832 3.71e-06 5 rs2307116 7.25e-06 8 rs13280242 5.64e-06 2 rs2708965 1.34e-05 3 rs10804692 1.37e-05
8 rs10216910 3.72e-06 3 rs10804692 7.60e-06 3 rs9820757 6.26e-06 2 rs2708963 1.34e-05 5 rs10520873 1.40e-05
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Table 24 6-month CrCl change: SNPs with the smallest p-values among Hispanics
CoCoBOT Additive Dominant Recessive Categorical
CHR SNP P CHR SNP P CHR SNP P CHR SNP P CHR SNP P
2 rs10432654 6.38e-08 5 rs7712026 3.12e-06 5 rs7712026 1.65e-06 1 rs12406740 2.62e-09 19 rs4807371 2.01e-08
20 rs6054512 2.82e-06 10 rs942525 3.67e-06 13 rs9520594 1.75e-06 19 rs4474816 2.62e-09 19 rs4474816 2.07e-08
5 rs10071986 2.85e-06 20 rs6054512 4.77e-06 10 rs942525 3.37e-06 19 rs3746073 2.62e-09 19 rs3746073 2.09e-08
3 rs7641490 3.02e-06 13 rs9520594 5.83e-06 1 rs213045 4.62e-06 19 rs4807371 2.62e-09 1 rs12406740 2.10e-08
5 rs6895299 3.11e-06 12 rs2292249 7.32e-06 5 rs3776801 6.63e-06 19 rs7251272 2.82e-09 19 rs7251272 2.26e-08
10 rs942525 3.22e-06 1 rs1572507 1.03e-05 15 rs4984592 1.14e-05 3 rs264079 5.03e-08 9 rs7872379 1.57e-07
14 rs2807769 3.87e-06 8 rs11987198 1.09e-05 2 rs10432654 1.46e-05 22 rs2055183 6.75e-08 6 rs7741934 2.10e-07
19 rs2607416 4.25e-06 5 rs3776801 1.13e-05 1 rs7552569 1.68e-05 9 rs7872379 8.41e-08 3 rs264079 2.45e-07
7 rs10953236 5.19e-06 2 rs10432654 1.17e-05 20 rs6054512 2.08e-05 22 rs17001167 9.32e-08 22 rs2055183 4.23e-07
1 rs7552569 6.06e-06 10 rs7893939 1.29e-05 8 rs11987198 2.19e-05 6 rs13206561 1.49e-07 6 rs13206561 5.45e-07
Table 25 shows the top 20 SNPs with the smallest p-values in the analysis of all subjects under each of
the five analysis models with baseline plasma bilirubin as outcome
Table 25 Baseline bilirubin: SNPs with the smallest p-values in combined group analysis
CoCoBOT Additive Dominant Recessive Categorical
CHR SNP P CHR SNP P CHR SNP P CHR SNP P CHR SNP P
2 rs4148324 1.29e-15 2 rs6742078 4.68e-17 2 rs3755319 2.23e-13 2 rs4148325 1.84e-16 2 rs6742078 5.26e-18
2 rs6742078 1.41e-15 2 rs4148324 4.71e-17 2 rs4663333 9.43e-10 2 rs887829 2.35e-16 2 rs4148324 7.84e-18
2 rs887829 3.89e-15 2 rs887829 1.46e-16 2 rs4399719 9.70e-10 2 rs6742078 3.12e-16 2 rs887829 9.45e-18
2 rs4148325 7.57e-15 2 rs4148325 2.94e-16 2 rs4124874 1.57e-09 2 rs4148324 6.32e-16 2 rs4148325 1.17e-17
2 rs3755319 8.01e-14 2 rs10179091 2.47e-14 2 rs4663967 1.70e-09 2 rs10179091 4.55e-13 2 rs3755319 4.52e-14
2 rs10179091 1.42e-13 2 rs3755319 2.72e-14 2 rs4663965 1.92e-09 2 rs4148326 6.93e-13 2 rs10179091 4.99e-14
2 rs4148326 6.05e-13 2 rs4148326 2.18e-13 2 rs6431628 2.87e-09 2 rs3771341 4.46e-11 2 rs4148326 2.37e-13
2 rs3771341 1.10e-11 2 rs3771341 9.72e-13 2 rs4148324 2.93e-09 2 rs929596 1.27e-10 2 rs3771341 6.31e-13
2 rs929596 5.80e-11 2 rs871514 1.71e-12 2 rs6742078 3.61e-09 2 rs17862875 3.15e-10 2 rs929596 1.87e-12
2 rs871514 6.93e-11 2 rs929596 3.19e-12 2 rs2008595 3.89e-09 2 rs2221198 2.45e-09 2 rs871514 1.54e-11
2 rs4294999 9.43e-11 2 rs4663965 3.22e-12 2 rs7572563 3.95e-09 2 rs4663969 2.81e-09 2 rs17862875 1.73e-11
2 rs4663965 1.09e-10 2 rs4294999 3.40e-12 2 rs3806597 4.39e-09 2 rs7556676 3.29e-09 2 rs4663965 2.69e-11
2 rs4663333 1.10e-10 2 rs4663333 4.80e-12 2 rs4294999 5.49e-09 2 rs7604115 6.26e-09 2 rs4294999 3.05e-11
2 rs4399719 1.79e-10 2 rs4663963 7.28e-12 2 rs17862866 6.47e-09 2 rs871514 6.60e-09 2 rs4663333 3.40e-11
2 rs2221198 1.83e-10 2 rs4663967 8.71e-12 2 rs4663963 7.21e-09 2 rs4294999 4.84e-08 2 rs4663967 6.22e-11
2 rs7556676 2.37e-10 2 rs3806597 1.15e-11 2 rs871514 8.32e-09 2 rs4663963 8.88e-08 2 rs4663963 6.37e-11
2 rs4663967 2.38e-10 2 rs4399719 1.73e-11 2 rs887829 1.63e-08 2 rs4663965 9.11e-08 2 rs3806597 9.30e-11
2 rs4663963 2.42e-10 2 rs6431628 3.23e-11 2 rs4148325 3.57e-08 5 rs35139949 1.05e-07 2 rs4399719 9.46e-11
2 rs4663969 2.64e-10 2 rs4124874 3.39e-11 2 rs3771341 1.00e-07 5 rs35981677 1.34e-07 2 rs4124874 1.81e-10
2 rs3806597 2.65e-10 2 rs2008595 3.79e-11 2 rs10179091 1.13e-07 2 rs3806597 1.66e-07 2 rs6431628 2.04e-10
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